WO2013185069A1 - Pulmonary delivery of mrna to non-lung target cells - Google Patents
Pulmonary delivery of mrna to non-lung target cells Download PDFInfo
- Publication number
- WO2013185069A1 WO2013185069A1 PCT/US2013/044771 US2013044771W WO2013185069A1 WO 2013185069 A1 WO2013185069 A1 WO 2013185069A1 US 2013044771 W US2013044771 W US 2013044771W WO 2013185069 A1 WO2013185069 A1 WO 2013185069A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- mrna
- composition
- lung
- cells
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/544—Mucosal route to the airways
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
Definitions
- gene therapy with DNA may result in the impairment of a vital genetic function in the treated host, such as e.g., elimination or deleteriously reduced production of an essential enzyme or interruption of a gene critical for the regulation of cell growth, resulting in unregulated or cancerous cell proliferation.
- a vital genetic function such as e.g., elimination or deleteriously reduced production of an essential enzyme or interruption of a gene critical for the regulation of cell growth, resulting in unregulated or cancerous cell proliferation.
- RNA does not involve the risk of being stably integrated into the genome of the transfected cell, thus eliminating the concern that the introduced genetic material will disrupt the normal functioning of an essential gene, or cause a mutation that results in deleterious or oncogenic effects; (2) extraneous promoter sequences are not required for effective translation of the encoded protein, again avoiding possible deleterious side effects; (3) in contrast to plasmid DNA (pDNA), messenger RNA (mRNA) is devoid of immunogenic CpG motifs so that anti-RNA antibodies are not generated; and (4) any deleterious effects that do result from mRNA based on gene therapy would be of limited duration due to the relatively short half-life of RNA.
- pDNA plasmid DNA
- mRNA messenger RNA
- any deleterious effects that do result from mRNA based on gene therapy would be of limited duration due to the relatively short half-life of RNA.
- the transient nature of mRNA transfer to cells i.e., wherein the duration of any therapeutic effect is limited by the life span of the mRNA and the protein product in the cells, is more desirable than the potentially longer lasting effect achieved using DNA based gene therapy.
- mRNA based gene therapy has not been used more in the past is that mRNA is far less stable than DNA, especially when it reaches the cytoplasm of a cell and is exposed to degrading enzymes.
- the presence of a hydroxyl group on the second carbon of the sugar moiety in mRNA causes steric hinderance that prevents the mRNA from forming the more stable double helix structure of DNA and thus makes the mRNA more prone to hydrolytic degradation.
- mRNA was too labile to withstand transfection protocols.
- RNA stabilizing modifications have sparked more interest in the use of mRNA in place of plasmid DNA in gene therapy. Yet, in spite of increased stability of modified mRNA, delivery of mRNA to cells in vivo in a manner allowing for therapeutic levels of protein production is still a challenge, particularly for mRNA encoding full length proteins.
- Some success has been achieved using viral vectors to introduce mRNA into a host, however mRNA transfection using viral vectors can result in an adverse immune response. In some circumstances, the viral vector may even integrate into the host genome.
- production of clinical grade viral vectors is also expensive and time consuming. Targeting delivery of the introduced genetic material using viral vectors can also be difficult to control.
- Non-viral delivery of mRNA can be achieved using injection of naked nucleic acids, polyplexes, lipoplexes or liposome entrapped mRNA, biolistic delivery via gene gun, particulate carrier mediated delivery, and electroporation.
- Non- viral transfection or delivery vehicles are generally less-toxic, less immunogenic, and easier and less expensive to prepare than viral vectors for delivery of mRNA.
- Certain delivery vehicles, such as cationic lipid or polymer delivery vehicles may also help protect the transfected mRNA from endogenous RNases.
- Liposomal delivery of nucleic acids has been employed as a means of effectuating the site-specific delivery of encapsulated plasmid DNA, antisense
- oligonucleotides short interfering RNA and microR A-based therapies.
- the efficient, therapeutically effective, delivery of mRNAs to targeted cells and tissues, as well as the subsequent transfection of such targeted cells and tissues remains a technical challenge, particularly for delivery of mRNAs encoding full length proteins. It is important to design liposomal delivery systems that provide sufficient stability to reach desired target cells and the ability to efficiently release their encapsulated materials to such target cells to allow for translation of functional protein at therapeutically effective levels.
- cationic lipids that are employed to construct such liposomal-based delivery vehicles are toxic to the targeted cells when used to deliver therapeutically effective amounts of the encapsulated agent. Accordingly, the toxicity associated with cationic lipid represents a significant obstacle to their general use as non-viral delivery vehicles, particularly in the quantities necessary to successfully deliver therapeutically effective amounts of mRNA to target cells.
- mRNA gene therapy benefits are relatively transient as compared to DNA based gene therapy, repeated administration, and typically by injection, are often required to provide long term effects.
- more efficient transfection in vivo and the ability to deliver mRNA noninvasively and/or to mucosal sites would improve the prospects for successful application of mRNA gene therapy.
- the present invention encompasses the surprising discovery that nanoparticle based formulations of mRNA are able to translocate following pulmonary delivery, i.e., move intact by either active or passive means from the lung to the systemic blood supply and subsequently to be deposited in different non-lung cells or tissues, such as, e.g., the liver.
- This translocation of the nanoparticle comprising an mRNA encoding a therapeutic protein, such as, e.g., beta-galactosidase constitutes non-invasive systemic delivery of an active pharmaceutical ingredient beyond the lung to result in the production of a functional protein to systemically accessible non-lung cells or tissues.
- the present invention provides methods for delivery of mRNA gene therapeutic agents using non- invasive pulmonary administrations.
- the present invention provides for the delivery of mRNA encoding a protein, which can be used in a method for treating and/or preventing a disease.
- the invention provides a method for delivery of messenger RNA (mRNA) to non-lung cell or tissue comprising administering to the lung a composition comprising mRNA encoding a protein and a lipid carrier vehicle, wherein the administering to the lung results in the delivery of the mRNA and/or the protein to a non-lung cell or tissue.
- mRNA messenger RNA
- the invention provides a method for delivery of a therapeutic protein to non- lung cell or tissue in a subject comprising administering to the lung a composition comprising mRNA encoding a therapeutic protein and a lipid carrier vehicle, such that the therapeutic protein is delivered to a non-lung cell or tissue.
- the invention provides a method of inducing the production of a therapeutic protein in a non- lung cell or tissue in a subject comprising administering to the lung a composition comprising mRNA encoding a therapeutic protein and a lipid carrier vehicle.
- the invention provides a method of treating a disease or disorder comprising administering to the lung a composition comprising mRNA encoding a therapeutic protein and a lipid carrier vehicle, wherein the administration to the lung results in the delivery of the therapeutic protein to a non- lung cell or tissue affected by the disease or disorder.
- the invention provides a composition for pulmonary delivery of messenger RNA (mRNA) comprising mRNA encoding a protein and a lipid carrier vehicle, wherein the composition is formulated such that once administered to the lung, it results in delivery of the mRNA and/or the protein to a non-lung cell or tissue.
- mRNA messenger RNA
- the composition is administered to the lung by aerosolization. In some embodiments, the composition is delivered to the lung by intratrachael aerosolization. In some embodiments, the composition is administered by nebulization. In some embodiments, the composition is administered to the lung by instillation. In some specific embodiments, the composition is administered to the lung of a subject using a device selected form the group consisting of a metered dose inhaler, jet- nebulizer, ultrasonic nebulizer, dry-powder-inhaler, propellant-based inhaler or an insufflator.
- the mRNA comprises a plurality of mRNA species, encoding one or more proteins. In some embodiments, the mRNA comprises at least two mRNA species, each encoding a different protein. In some embodiments, the mRNA encodes a full length protein. In some embodiments, the mRNA encodes a truncated version of a naturally occurring full length protein. In some embodiments, the mRNA encodes one or more proteins in a single transcript. In some embodiments, the mRNA encodes a chimeric protein, in which one or more protein sequences which are not naturally associated with the native protein are linked by a peptide bond in the resulting chimeric protein during expression.
- an mRNA suitable for the present invention has a length of or greater than about 0.5kb, lkb, 1.5kb, 2.0kb, 2.5kb, 3.0kb, 3.5kb, 4.0kb, 4.5kb, or 5.0kb.
- the mRNA encodes an intracellular protein. In some embodiments, the mRNA encodes a cytosolic protein. In some embodiments, the mRNA encodes a protein associated with the actin cytoskeleton. In some embodiments, the mRNA encodes a protein associated with the plasma membrane. In some specific embodiments, the mRNA encodes a transmembrane protein. In some specific embodiments, the mRNA encodes an ion channel protein. In some embodiments, the mRNA encodes a perinuclear protein. In some embodiments, the mRNA encodes a nuclear protein. In some specific embodiments, the mRNA encodes a transcription factor.
- the mRNA encodes a chaperone protein. In some embodiments, the mRNA encodes an intracellular enzyme. In some embodiments, the mRNA encodes a protein involved in cellular metabolism, DNA repair, transcription and/or translation. In some embodiments, the mRNA encodes an extracellular protein. In some embodiments, the mRNA encodes a protein associated with the extracellular matrix. In some embodiments the mRNA encodes a secreted protein.
- the mRNA encodes a protein (i.e. therapeutic protein), listed in Table 1, 2, 3 or 4.
- the protein is selected from the group consisting of alpha galactosidase, erythropoietin, a 1 -antitrypsin, carboxypeptidase N, alpha-L-iduronidase, iduronate-2-sulfatase, N-acetylglucosamine-1 -phosphate transferase, N- acetylglucosaminidase, lysosomal acid lipase, arylsulfatase-A alpha-glucosaminide acetyltransferase, N-acetylglucosamine 6-sulfatase, N-acetylgalactosamine-4-sulfatase, beta- glucosidase, galactose-6-sulfate sulfat
- argininosuccinate synthetase-1 ASS1
- ASL argininosuccinate lyase
- ARG1 arginase-1
- CFTR cystic fibrosis transmembrane conductance regulator
- the mRNA encodes a protein that is associated with a disease or disorder (i.e., indication) listed in Table 4.
- the protein for use in the method is selected based on its ability to prevent, treat and/or cure a subject affected with a disease or disorder (i.e., indication) listed in Table 4.
- the disease or disorder is selected from the group consisting of SMN1 -related spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), GALT -related galactosemia, Cystic Fibrosis (CF), SLC3A1 -related disorders, cystinuria, COL4A5 -related disorders, Alport syndrome, galactocerebrosidase deficiencies, X-linked
- adrenoleukodystrophy adrenomyeloneuropathy, Friedreich's ataxia, Pelizaeus-Merzbacher disease, TSC1 or TSC2-related tuberous sclerosis, Sanfilippo B syndrome (MPS IIIB), CTNS-related cystinosis
- the FMR1 -related disorders include Fragile X syndrome, Fragile X-Associated Tremor/Ataxia Syndrome, Fragile X Premature Ovarian Failure Syndrome, Prader-Willi syndrome, Fabry disease, hereditary hemorrhagic telangiectasia (AT), Niemann- Pick disease Type CI, neuronal ceroid lipofuscinoses-related diseases, Juvenile Neuronal Ceroid Lipofuscinosis (JNCL), Juvenile Batten disease, Santavuori-Haltia disease, Jansky- Bielschowsky disease, PTT-1 deficiency, TPP1 deficiency, EIF2B 1, EIF2B2, EIF
- CACNA1A and CACNB4-related Episodic Ataxia Type 2 the MECP2 -related disorders, Classic Rett Syndrome, MECP2-related Severe Neonatal Encephalopathy, PPM-X Syndrome, CDKL5 -related Atypical Rett Syndrome, Kennedy's disease (SBMA), Notch-3 related cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), SCN1A and SCN IB-related seizure disorders, Polymerase G-related disorders, Alpers-Huttenlocher syndrome, POLG- related sensory ataxic neuropathy, dysarthria, ophthalmoparesis, autosomal dominant and recessive progressive external ophthalmoplegia with mitochondrial DNA deletions, X-Linked adrenal hypoplasia, X-linked agammaglobulinemia, Wilson's disease, and blood clotting disorders.
- the mRNA and/or protein is delivered to a non-lung tissue.
- the non-lung tissue comprises any organ and/or organ system of the body, excluding the lungs.
- the non-lung tissue is selected from the group consisting of heart, liver, spleen, kidneys, skeletal muscle, lymph nodes, brain skin, cerebrospinal fluid, plasma and combinations thereof.
- the non-lung tissue is liver.
- the non-lung tissue is heart.
- the non- lung tissue is spleen.
- the mRNA and/or protein is delivered to a non-lung cell.
- the non-lung cell is selected from the group consisting of hepatocytes, epithelial cells, hematopoietic cells, epithelial cells, endothelial cells, bone cells, stem cells, mesenchymal cells, neural cells, cardiac cells, adipocytes, vascular smooth muscle cells, cardiomyocytes, skeletal muscle cells, beta cells, pituitary cells, synovial lining cells, ovarian cells, testicular cells, fibroblasts, B cells, T cells, reticulocytes, leukocytes, granulocytes, tumor cells, macrophages, neutrophils, antigen presenting cells (dendritic cells), fibroblasts and combination thereof.
- the non-lung cell is a hepatocyte.
- the mRNA and/or protein is detectable in the non-lung cell and/or tissue for at least about 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 18 hiurs, 24 hours, or more following the administration to the lung. In some embodiments, the mRNA and/or protein is detectable in the non-lung cell and/or tissue for at least about 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days or 10 days following the administration to the lung.
- the mRNA and/or protein is detectable in the non-lung cell and/or tissue for at least about 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, or 6 weeks following administration to the lung.
- the mRNA is detected using a methods selected the group consisting of in-situ hybridization, RT-PCR, Real-Time RT- PCR, Northern Blot, nuclease protection assay and combinations thereof.
- the protein is detected using a methods selected from the group consisting of Western Blot, ELISA, immunoprecipitation, BCA assay, immunohistochemistry and combinations thereof.
- the mRNA is delivered at an amount greater than about
- 0.5 mg/kg e.g., greater than about 1.0 mg/kg, 1.5 mg/kg, 2.0 mg/kg, 2.5 mg/kg, 3.0 mg/kg, 4.0 mg/kg, 5.0 mg/kg, 6.0 mg/kg, 7.0 mg/kg, 8.0 mg/kg, 9.0 mg/kg, or 10.0 mg/kg body weigth of mRNA per dose.
- the mRNA is delivered at an amount ranging from about 0.1-100 mg/kg (e.g., about 0.1-90 mg/kg, 0.1-80 mg/kg, 0.1-70 mg/kg, 0.1-60 mg/kg, 0.1-50 mg/kg, 0.1-40 mg/kg, 0.1-30 mg/kg, 0.1-20 mg/kg, 0.1-10 mg/kg) body weight of mRNA per dose.
- 0.1-100 mg/kg e.g., about 0.1-90 mg/kg, 0.1-80 mg/kg, 0.1-70 mg/kg, 0.1-60 mg/kg, 0.1-50 mg/kg, 0.1-40 mg/kg, 0.1-30 mg/kg, 0.1-20 mg/kg, 0.1-10 mg/kg
- the mRNA is delivered at an amount of or greater than about 1 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, or 500 mg per dose.
- the mRNA is encapsulated in a single lipid carrier vehicle. In some embodiments, the mRNA is encapsulated in one or more lipid carrier vehicles. In some embodiments, the mRNA is encapsulated in one or more lipid carrier vehicles, which differ in their lipid composition, molar ratio of lipid components, size, charge (Zeta potential), targeting ligands and combinations thereof.
- the lipid carrier vehicle is a liposome.
- the liposome comprises one or more cationic lipids, one or more non-cationic lipids, one or more cholesterol-based lipids and one or more PEG-modified lipids.
- the one or more cationic lipid is an ionizable lipid.
- the one or more cationic lipid is a cleavable lipid.
- the one or more cationic lipid is a cholesterol-derived cationic lipid.
- the one or more cationic lipids are selected from C12-200, HGT4003, HGT5000, HGT5001, RE-1, RE-2, RE- 3, ICE, GL-67, DLinKC2-DMA, DODAP, DODMA, DLinDMA, CLinDMA and combinations thereof.
- the composition further comprises a pulmonary surfactant.
- the composition is formulated as respirable particles.
- the respirable particles have a size less than about 500 ⁇ (e.g., less than about 450 ⁇ , 400 ⁇ , 350 ⁇ , 300 ⁇ , 250 ⁇ , 200 ⁇ , 150 ⁇ , ⁇ , or 50 ⁇ ).
- the composition is formulated as a nebulizable lipid.
- the composition is formulated as a dry powder.
- the invention also provides a composition comprising mRNA encoding a protein and a lipid carrier vehicle as described herein for use in a method of delivery of messenger RNA (mRNA) to a non-lung cell or tissue, wherein the method comprises a step of administering the composition to the lung of a subject and further wherein the administering to the lung results in the delivery of the mRNA and/or protein to the non-lung cell or tissue.
- mRNA messenger RNA
- the invention provides a composition comprising mRNA encoding a protein and a lipid carrier vehicle as described herein for use in a method for delivery of therapeutic protein to a non-lung cell or tissue, wherein the method comprises a step of administering the composition to the lung of a subject.
- the invention provides a composition comprising mRNA encoding a protein and a lipid carrier vehicle as described herein for use in a method for inducing the production of a protein in a non-lung cell or tissue, wherein the method comprises a step of administering the composition to the lung.
- the invention provides a composition comprising mRNA encoding a protein and a lipid carrier vehicle as described herein for use in treating a disease or disorder, wherein the method comprises a step of administering the composition to the lung and further wherein the administering to the lung results in the delivery of mRNA and/or protein to a non-lung cell or tissue affected by the disease or disorder.
- the terms "about” and “approximately” are used as equivalents. Any numerals used in this application with or without about/approximately are meant to cover any normal fluctuations appreciated by one of ordinary skill in the relevant art.
- Figure 1 shows bioluminescence Imaging (BLI) of mice at 6 hrs post intratracheal (IT) spray application.
- Panels 1, 2, 3 show protein production in mice treated with naked FFL mRNA compared with protein production in mice treated with FFL mRNA in C12-200:DOPE: Cholesterol: DMG-PEG2000 (40:30:25:5) nanoparticles (NPs) in panels 4, 5, 6.
- Panels 1, 2 naked modified FFL mRNA
- panels 3, 4, 5 modified FFL mRNA in CI 2-200 based NPs.
- FIG. 1 shows BLI at 6 hrs post IT spray application using BLI.
- FIG. 3 shows BLI images of mice post IT spray application.
- Figure 4 shows BLI images of mice treated with naked FFL mRNA at 24 hrs post applications. Panels 1, 2 (24 hours after first application); panels 3, 4 (24 hours after second application); panels 5, 6 (24 hours after third application).
- Figure 5 shows BLI images of mice treated with naked modified FFL mRNA at 24 hrs post application. Panels (24 hours after first application); panels 3, 4 (24 hours after second application); panels 5, 6 (24 hours after third application).
- FIG. 6 shows BLI images of mice at 6 hours post IT spray application.
- Panels 1, 2 (FFL mRNA in C12-200 based NPs (10 ⁇ g/mouse)); panels 3, 4 (FFL mRNA in C12-200 based NPs (5 ⁇ g/mouse).
- Panel 1 (modified FFL mRNA in C12-200 based NPs (10 ⁇ g/mouse)); panels 2, 3 (modified FFL mRNA in C12-200 based NPs (5 ⁇ g/mouse).
- Figure 7 shows BLI images of mice at 6 hrs and 24 post IT spray application at doses of 10 ⁇ g/mouse.
- A All mice (FFL mRNA in CI 2-200 based NPs); panels 1, 2 (24 hours); panels 3, 4 (6 hours).
- B All mice (modified FFL mRNA in CI 2-200 based NPs); panel 1 (24 hours); panel 2 (6 hours).
- C Comparison of panels 1, 2 (FFL mRNA in C12- 200 based NPs) with panel 3 (modified FFL mRNA in CI 2-200 based NPs) at 24 hrs post IT spray.
- Figure 8 shows biodistribution of FFL and modified FFL mRNA in C 12-200 based NPs at 5 or 10 ⁇ g/mouse doses post IT spray.
- Figure 9 shows BLI images of mice at 6 hrs post IT spray application. Panels
- Figure 10 shows BLI images of mice at 6 hrs (panels 1, 2) and 24 hrs (panels
- HGT5001 DOPE:Cholesterol:DMG-PEG2000 (40:20:35:5) nanoparticles at doses of 10 ⁇ g/mouse.
- Figure 11 shows BLI image of mice at 24 hrs post IT spray application.
- Figure 12 shows FFL luminescence detected in lung, liver of mice after a single, intravenous injection treatment of mRNA-encapsulated lipid nanoparticles formulations, C12-200:DOPE:Cholesterol:DMG-PEG2000 (40:30:25:5) and
- HGT5001 DOPE:Cholesterol: DMG-PEG2000 (40:20:35:5). Mice were sacrificed at 6 hr and 24 hr post-administration.
- Figure 13 shows BLI images of mice 6 hours post nebulization with modified
- amino acid in its broadest sense, refers to any compound and/or substance that can be incorporated into a polypeptide chain.
- an amino acid has the general structure H 2 N-C(H)(R)-COOH.
- an amino acid is a naturally occurring amino acid.
- an amino acid is a synthetic amino acid; in some embodiments, an amino acid is a d-amino acid; in some embodiments, an amino acid is an 1-amino acid.
- Standard amino acid refers to any of the twenty standard 1-amino acids commonly found in naturally occurring peptides.
- Nonstandard amino acid refers to any amino acid, other than the standard amino acids, regardless of whether it is prepared synthetically or obtained from a natural source.
- synthetic amino acid encompasses chemically modified amino acids, including but not limited to salts, amino acid derivatives (such as amides), and/or substitutions.
- Amino acids, including carboxy- and/or amino-terminal amino acids in peptides can be modified by methylation, amidation, acetylation, protecting groups, and/or substitution with other chemical groups that can change the peptide's circulating half-life without adversely affecting their activity. Amino acids may participate in a disulfide bond.
- Amino acids may comprise one or posttranslational modifications, such as association with one or more chemical entities (e.g., methyl groups, acetate groups, acetyl groups, phosphate groups, formyl moieties, isoprenoid groups, sulfate groups, polyethylene glycol moieties, lipid moieties, carbohydrate moieties, biotin moieties, etc.).
- chemical entities e.g., methyl groups, acetate groups, acetyl groups, phosphate groups, formyl moieties, isoprenoid groups, sulfate groups, polyethylene glycol moieties, lipid moieties, carbohydrate moieties, biotin moieties, etc.
- amino acid is used interchangeably with "amino acid residue,” and may refer to a free amino acid and/or to an amino acid residue of a peptide. It will be apparent from the context in which the term is used whether it refers to a free amino acid or a residue of a
- animal refers to any member of the animal kingdom. In some embodiments, “animal” refers to humans, at any stage of development. In some embodiments, “animal” refers to non-human animals, at any stage of development. In certain embodiments, the non-human animal is a mammal (e.g., a rodent, a mouse, a rat, a rabbit, a monkey, a dog, a cat, a sheep, cattle, a primate, and/or a pig). In some of a mammal (e.g., a rodent, a mouse, a rat, a rabbit, a monkey, a dog, a cat, a sheep, cattle, a primate, and/or a pig). In some embodiments, a mammal (e.g., a rodent, a mouse, a rat, a rabbit, a monkey, a dog, a cat, a sheep, cattle, a primate, and/or a pig). In
- animals include, but are not limited to, mammals, birds, reptiles, amphibians, fish, insects, and/or worms.
- an animal may be a transgenic animal, genetically-engineered animal, and/or a clone.
- Dosing regimen is a set of unit doses (typically more than one) that are administered individually to a subject, typically separated by periods of time.
- a given therapeutic agent has a recommended dosing regiment, which may involve one or more doses.
- a dosing regimen comprises a plurality of doses each of which are separated from one another by a time period of the same length; in some embodiments, a dosing regime comprises a plurality of doses and at least two different time periods separating individual doses.
- expression of a nucleic acid sequence refers to one or more of the following events: (1) production of an RNA template from a DNA sequence (e.g., by transcription); (2) processing of an RNA transcript (e.g., by splicing, editing, 5' cap formation, and/or 3 ' end formation); (3) translation of an RNA into a polypeptide or protein; and/or (4) post-translational modification of a polypeptide or protein.
- expression and “production,” and grammatical equivalent, are used inter-changeably.
- improve As used herein, the terms “improve,” “increase” or “reduce,” or grammatical equivalents, indicate values that are relative to a baseline measurement, such as a measurement in the same individual prior to initiation of the treatment described herein, or a measurement in a control subject (or multiple control subject) in the absence of the treatment described herein.
- a “control subject” is a subject afflicted with the same form of disease as the subject being treated, who is about the same age as the subject being treated.
- in vitro refers to events that occur in an artificial environment, e.g., in a test tube or reaction vessel, in cell culture, etc., rather than within a multi-cellular organism.
- in vivo refers to events that occur within a multi-cellular organism, such as a human and a non-human animal. In the context of cell- based systems, the term may be used to refer to events that occur within a living cell (as opposed to, for example, in vitro systems).
- messenger RNA As used herein, the term "messenger RNA
- mRNA refers to a polynucleotide that encodes at least one polypeptide.
- mRNA as used herein encompasses both modified and unmodified RNA.
- mRNA may contain one or more coding and non-coding regions.
- nucleic acid As used herein, the term “nucleic acid,” in its broadest sense, refers to any compound and/or substance that is or can be incorporated into a polynucleotide chain. In some embodiments, a nucleic acid is a compound and/or substance that is or can be incorporated into a polynucleotide chain via a phosphodiester linkage. In some
- nucleic acid refers to individual nucleic acid residues (e.g., nucleotides and/or nucleosides). In some embodiments, “nucleic acid” refers to a polynucleotide chain comprising individual nucleic acid residues. In some embodiments, “nucleic acid” encompasses RNA as well as single and/or double-stranded DNA and/or cDNA.
- nucleic acid includes nucleic acid analogs, i.e., analogs having other than a phosphodiester backbone.
- nucleic acid analogs i.e., analogs having other than a phosphodiester backbone.
- peptide nucleic acids which are known in the art and have peptide bonds instead of phosphodiester bonds in the backbone, are considered within the scope of the present invention.
- nucleotide sequence encoding an amino acid sequence includes all nucleotide sequences that are degenerate versions of each other and/or encode the same amino acid sequence. Nucleotide sequences that encode proteins and/or RNA may include introns.
- nucleic acids can be purified from natural sources, produced using recombinant expression systems and optionally purified, chemically synthesized, etc. Where appropriate, e.g., in the case of chemically synthesized molecules, nucleic acids can comprise nucleoside analogs such as analogs having chemically modified bases or sugars, backbone
- nucleic acid sequence is presented in the 5' to 3 ' direction unless otherwise indicated.
- a nucleic acid is or comprises natural nucleosides (e.g., adenosine, thymidine, guanosine, cytidine, uridine, deoxy adenosine, deoxythymidine, deoxy guanosine, and deoxycytidine); nucleoside analogs (e.g., 2- aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyl adenosine, 5- methylcytidine, C-5 propynyl-cytidine, C-5 propynyl-uridine, 2-aminoadenosine, C5- bromouridine, C5-fluorouridine, C5-iodouridine, C5 -propynyl-uridine, C5 -propynyl-c
- the present invention is specifically directed to "unmodified nucleic acids,” meaning nucleic acids (e.g., polynucleotides and residues, including nucleotides and/or nucleosides) that have not been chemically modified in order to facilitate or achieve delivery.
- nucleic acids e.g., polynucleotides and residues, including nucleotides and/or nucleosides
- patient refers to any organism to which a provided composition may be administered, e.g., for experimental, diagnostic, prophylactic, cosmetic, and/or therapeutic purposes.
- Typical patients include animals (e.g., mammals such as mice, rats, rabbits, non-human primates, and/or humans).
- animals e.g., mammals such as mice, rats, rabbits, non-human primates, and/or humans.
- a patient is a human.
- a human includes pre and post natal forms.
- compositions that, within the scope of sound medical judgment, are suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- Polypeptide As used herein, a "polypeptide”, generally speaking, is a string of at least two amino acids attached to one another by a peptide bond. In some embodiments, a polypeptide may include at least 3-5 amino acids, each of which is attached to others by way of at least one peptide bond. Those of ordinary skill in the art will appreciate that polypeptides sometimes include "non-natural" amino acids or other entities that nonetheless are capable of integrating into a polypeptide chain, optionally.
- Protein As used herein, the term "protein” of "therapeutic protein” refers to a polypeptide (i.e., a string of at least two amino acids linked to one another by peptide bonds). Proteins may include moieties other than amino acids (e.g., may be glycoproteins, proteoglycans, etc.) and/or may be otherwise processed or modified. Those of ordinary skill in the art will appreciate that a “protein” can be a complete polypeptide chain as produced by a cell (with or without a signal sequence), or can be a characteristic portion thereof. Those of ordinary skill will appreciate that a protein can sometimes include more than one polypeptide chain, for example linked by one or more disulfide bonds or associated by other means.
- Polypeptides may contain 1-amino acids, d-amino acids, or both and may contain any of a variety of amino acid modifications or analogs known in the art. Useful modifications include, e.g., terminal acetylation, amidation, methylation, etc.
- proteins may comprise natural amino acids, non-natural amino acids, synthetic amino acids, and combinations thereof.
- the term "peptide” is generally used to refer to a polypeptide having a length of less than about 100 amino acids, less than about 50 amino acids, less than 20 amino acids, or less than 10 amino acids.
- proteins are antibodies, antibody fragments, biologically active portions thereof, and/or characteristic portions thereof.
- Subject refers to a human or any non-human animal (e.g., mouse, rat, rabbit, dog, cat, cattle, swine, sheep, horse or primate).
- a human includes pre- and post-natal forms.
- a subject is a human being.
- a subject can be a patient, which refers to a human presenting to a medical provider for diagnosis or treatment of a disease.
- the term "subject” is used herein interchangeably with "individual” or "patient.”
- a subject can be afflicted with or is susceptible to a disease or disorder but may or may not display symptoms of the disease or disorder.
- therapeutically effective amount As used herein, the term "therapeutically effective amount" of a therapeutic agent means an amount that is sufficient, when administered to a subject suffering from or susceptible to a disease, disorder, and/or condition, to treat, diagnose, prevent, and/or delay the onset of the symptom(s) of the disease, disorder, and/or condition. It will be appreciated by those of ordinary skill in the art that a therapeutically effective amount is typically administered via a dosing regimen comprising at least one unit dose.
- treatment refers to any administration of a substance (e.g., provided compositions) that partially or completely alleviates, ameliorates, relives, inhibits, delays onset of, reduces severity of, and/or reduces incidence of one or more symptoms, features, and/or causes of a particular disease, disorder, and/or condition (e.g., influenza).
- a substance e.g., provided compositions
- Such treatment may be of a subject who does not exhibit signs of the relevant disease, disorder and/or condition and/or of a subject who exhibits only early signs of the disease, disorder, and/or condition.
- such treatment may be of a subject who exhibits one or more established signs of the relevant disease, disorder and/or condition.
- treatment may be of a subject who has been diagnosed as suffering from the relevant disease, disorder, and/or condition. In some embodiments, treatment may be of a subject known to have one or more susceptibility factors that are statistically correlated with increased risk of development of the relevant disease, disorder, and/or condition.
- the present invention provides, among other things, methods and
- compositions for systemic delivery of mRNA and/or its protein product based on pulmonary delivery provides a method of administering a composition comprising mRNA and a lipid carrier vehicle to the lungs of a subject, for delivery of the mRNA and/or protein to non-lung cells and tissues.
- mRNA encoding a single protein are delivered.
- one or more mRNA species encoding one or more proteins are delivered.
- the mRNA is delivered using a single lipid carrier vehicle (e.g. liposome or lipid-derived nanoparticle).
- the mRNA is delivered using a one or more lipid carrier vehicles.
- mRNAs according to the present invention may be synthesized according to any of a variety of known methods.
- mRNAs according to the present invention may be synthesized via in vitro transcription (IVT).
- IVT in vitro transcription
- IVT is typically performed with a linear or circular DNA template containing a promoter, a pool of ribonucleotide triphosphates, a buffer system that may include DTT and magnesium ions, and an appropriate RNA polymerase (e.g., T3, T7 or SP6 RNA polymerase), DNAse I, pyrophosphatase, and/or RNAse inhibitor.
- RNA polymerase e.g., T3, T7 or SP6 RNA polymerase
- a DNA template is transcribed in vitro.
- a suitable DNA template typically has a promoter, for example a T3, T7 or SP6 promoter, for in vitro transcription, followed by desired nucleotide sequence for a desired mRNA and a termination signal.
- Desired mRNA sequence according to the invention may be determined and incorporated into a DNA template using standard methods. For example, starting from a desired amino acid sequence a virtual reverse translation is carried out based on the degenerated genetic code. Optimization algorithms may then be used for selection of suitable codons. Typically, the G/C content can be optimized to achieve the highest possible G/C content on one hand, taking into the best possible account the frequency of the tRNAs according to codon usage on the other hand. The optimized RNA sequence can be established and displayed, for example, with the aid of an appropriate display device and compared with the original (wild-type) sequence. A secondary structure can also be analyzed to calculate stabilizing and destabilizing properties or, respectively, regions of the RNA.
- mRNA according to the present invention may be synthesized as unmodified or modified mRNA.
- the mRNA may include one or more chemical or structural modifications to abrogate mRNA interaction with toll-like receptors TLR3, TLR7, TLR8, and retinoid-inducible gene I (RIG-I) to reduce immunogenicity as well as improve stability of the mRNA.
- toll-like receptors TLR3, TLR7, TLR8, and retinoid-inducible gene I (RIG-I) to reduce immunogenicity as well as improve stability of the mRNA.
- the mRNA may be modified as described in U.S. patent publication 2009/0286852 (incorporated herein by reference), to comprise one or more pseudouridine residues.
- Kormann et al., Nature Biotechnology 29(2): 154-157 (2011) describe replacement of uridine and cytidine with 2-thiouridine and 5- methylcytidine to synergistically decrease mRNA binding to pattern recognition receptors TLR3, TLR7, TLR8, and RIG-I and increase stability of the mRNA. See EP2459231.
- the mRNA may be modified to reduce immunogenicity as described in European Application EP 10742089 (incorporated herein by reference).
- modifications of mRNA can include, for example, modifications of the nucleotides of the RNA.
- An modified mRNA according to the invention can thus include, for example, backbone modifications, sugar modifications or base modifications.
- mRNAs encoding a protein of interest may be synthesized from naturally occurring nucleotides and/or nucleotide analogues (modified nucleotides) including, but not limited to, purines (adenine (A), guanine (G)) or pyrimidines (thymine (T), cytosine (C), uracil (U)), and as modified nucleotides analogues or derivatives of purines and pyrimidines, such as e.g.
- mRNAs may contain RNA backbone modifications.
- a backbone modification is a modification in which the phosphates of the backbone of the nucleotides contained in the RNA are modified chemically.
- exemplary backbone modifications typically include, but are not limited to, modifications from the group consisting of methylphosphonates, methylphosphoramidates, phosphoramidates, phosphorothioates (e.g. cytidine 5'-0-(l-thiophosphate)), boranophosphates, positively charged guanidinium groups etc., which means by replacing the phosphodiester linkage by other anionic, cationic or neutral groups.
- mRNAs may contain sugar modifications.
- a typical sugar modification is a chemical modification of the sugar of the nucleotides it contains including, but not limited to, sugar modifications chosen from the group consisting of 2'- deoxy-2'-fluoro-oligoribonucleotide (2'-fluoro-2'-deoxycytidine 5 '-triphosphate, 2'-fluoro-2'- deoxyuridine 5'-triphosphate), 2'-deoxy-2'-deamine-oligoribonucleotide (2'-amino-2'- deoxycytidine 5 '-triphosphate, 2'-amino-2'-deoxyuridine 5 '-triphosphate), 2'-0- alkyloligoribonucleotide, 2'-deoxy-2'-C-alkyloligoribonucleotide (2'-0-methylcytidine 5'- triphosphate, 2'-methyluridine 5 '-triphosphate), 2'-C-alky
- mRNAs may contain modifications of the bases of the nucleotides (base modifications).
- a modified nucleotide which contains a base modification is also called a base-modified nucleotide.
- base-modified nucleotides include, but are not limited to, 2-amino-6-chloropurine riboside 5 '-triphosphate, 2- aminoadenosine 5'-triphosphate, 2-thiocytidine 5'-triphosphate, 2-thiouridine 5 '-triphosphate,
- 6- chloropurine riboside 5 '-triphosphate 7-deazaadenosine 5 '-triphosphate, 7-deazaguanosine 5 '-triphosphate, 8-azaadenosine 5 '-triphosphate, 8-azidoadenosine 5 '-triphosphate, benzimidazole riboside 5'-triphosphate, Nl-methyladenosine 5 '-triphosphate, Nl- methylguanosine 5 '-triphosphate, N6-methyladenosine 5 '-triphosphate, 06-methylguanosine 5 '-triphosphate, pseudouridine 5 '-triphosphate, puromycin 5'-triphosphate or xanthosine 5'- triphosphate.
- stabilizing modifications may be made to either or both the 3 ' and 5' ends of the mRNA and include, e.g., end capping, polyA tail, replacement of unstable non-coding sequences (such as adenylate uridylate rich elements (AREs) or addition or 3 ' or 5' untranslated sequences from stable mRNA (such as, e.g., ⁇ -globin, actin, GAPDH, tubulin, histone, or citric acid cycle enzyme mRNA).
- unstable non-coding sequences such as adenylate uridylate rich elements (AREs)
- AREs adenylate uridylate rich elements
- 3 ' or 5' untranslated sequences from stable mRNA such as, e.g., ⁇ -globin, actin, GAPDH, tubulin, histone, or citric acid cycle enzyme mRNA.
- Stabilizing modifications may also be made within the mRNA, and include, e.g., codon optimization and/or modification of the Kozak sequence, and/or incorporation of modified nucleosides (such as, e.g., pyrrolo-pyrimidine, C5-iodouridine, 2-amino adenosine, and 2-thiothymidine).
- modified nucleosides such as, e.g., pyrrolo-pyrimidine, C5-iodouridine, 2-amino adenosine, and 2-thiothymidine.
- the modified mRNA used in the methods and compositions of the invention include a 5' untranslated sequence from CMV immediate-early 1 (IE1) gene:
- X if present is GGA (SEQ ID NO: 1), or a sequence that is at least 90% or at least 95% identical to SEQ ID NO: 1, or a and/or a 3 'untranslated sequence from human growth hormone (hGH) gene:
- mRNA synthesis includes the addition of a "cap" on the N-terminal
- mRNAs of the current invention include a 5' cap structure.
- a 5' cap is typically added as follows: first, an RNA terminal phosphatase removes one of the terminal phosphate groups from the 5' nucleotide, leaving two terminal phosphates; guanosine triphosphate (GTP) is then added to the terminal phosphates via a guanylyl transferase, producing a 5'5'5 triphosphate linkage; and the 7-nitrogen of guanine is then methylated by a methyltransferase.
- GTP guanosine triphosphate
- cap structures include, but are not limited to, m7G(5')ppp (5'(A,G(5')ppp(5')A and G(5')ppp(5')G.
- mRNAs of the current invention include a 3 ' poly(A) tail structure.
- a poly-A tail on the 3' terminus of mRNA typically includes about 10 to 300 adenosine nucleotides (e.g., about 10 to 200 adenosine nucleotides, about 10 to 150 adenosine nucleotides, about 10 to 100 adenosine nucleotides, about 20 to 70 adenosine nucleotides, or about 20 to 60 adenosine nucleotides).
- mRNAs of the current invention include a 3 ' poly(C) tail structure.
- a suitable poly-C tail on the 3' terminus of mRNA typically include about 10 to 200 cytosine nucleotides (e.g., about 10 to 150 cytosine nucleotides, about 10 to 100 cytosine nucleotides, about 20 to 70 cytosine nucleotides, about 20 to 60 cytosine nucleotides, or about 10 to 40 cytosine nucleotides).
- the poly-C tail may be added to the poly-A tail or may substitute the poly-A tail.
- mRNAs of the current invention include a 5' and/or 3 ' untranslated region.
- a 5' untranslated region includes one or more elements that affect an mRNA's stability or translation, for example, an iron responsive element.
- a 5' untranslated region may be between about 50 and 500 nucleotides in length.
- a 3 ' untranslated region includes one or more of a polyadenylation signal, a binding site for proteins that affect an mRNA's stability of location in a cell, or one or more binding sites for miRNAs.
- a 3' untranslated region may be between 50 and 500 nucleotides in length or longer.
- the mRNAs used in the compositions and methods of the invention may be used to express full length, truncated, native or modified protein for delivery to non-lung tissue and cells.
- the mRNA comprises at least one mRNA species encoding a protein (i.e. a therapeutic protein).
- the mRNA comprises a plurality of mRNA species, encoding one or more gene products.
- the mRNA comprises at least two mRNA species, each encoding a different gene product.
- the mRNA encodes a full length protein.
- the mRNA encode a truncated version of the naturally occurring full length protein.
- the mRNA encode one or more truncated protein from different gene products in a single transcript.
- the mRNA encodes a chimeric protein, in which one or more protein sequences which are not naturally associated with the native protein are linked by a peptide bond in the resulting chimeric protein during expression.
- the mRNA may be used to express a partial or full length protein comprising cellular activity at a level equal to or greater than that of the native protein.
- the mRNA may be used to express a partial or full length protein with cellular activity at a level equal to or less than that of the native protein.
- the mRNA encodes an intracellular protein. In some embodiments, the mRNA encodes a cytosolic protein. In some embodiments, the mRNA encodes a protein associated with the actin cytoskeleton. In some embodiments, the mRNA encodes a protein associated with the plasma membrane. In some specific embodiments, the mRNA encodes a transmembrane protein. In some specific embodiments the mRNA encodes an ion channel protein. In some embodiments, the mRNA encodes a perinuclear protein. In some embodiments, the mRNA encodes a nuclear protein. In some specific embodiments, the mRNA encodes a transcription factor. In some embodiments, the mRNA encodes a chaperone protein.
- the mRNA encodes an intracellular enzyme (e.g., mRNA encoding an enzyme associated with urea cycle or lysosomal storage metabolic disorders).
- the mRNA encodes a protein involved in cellular metabolism, DNA repair, transcription and/or translation.
- the mRNA encodes an extracellular protein.
- the mRNA encodes a protein associated with the extracellular matrix.
- the mRNA encodes a secreted protein.
- the mRNA used in the composition and methods of the invention may be used to express functional proteins or enzymes that are excreted or secreted by one or more target cells into the surrounding extracellular fluid (e.g., mRNA encoding hormones and neurotransmitters)
- compositions and methods of the invention provide for delivery of mRNA encoding a secreted protein.
- the compositions and methods of the invention provide for delivery of mRNA encoding one or more secreted proteins listed in Table 1; thus, compositions of the invention may comprise an mRNA encoding a protein listed in Table 1 (or a homolog thereof, as discussed below) along with other components set out herein, and methods of the invention may comprise preparing and/or administering a composition comprising an mRNA encoding a protein listed in Table 1 (or a homolog thereof, as discussed below) along with other components set out herein.
- J3KNZ1 Choriogonadotropin subunit beta variant 1 CGB1
- J3KP00 Choriogonadotropin subunit beta CGB7
- TNFSF11 member 11 Tumor necrosis factor ligand superfamily TNFSF11 member 11 , membrane form
- P35858 Insulin-like growth factor-binding protein IGFALS complex acid labile subunit
- P59510 A disintegrin and metalloproteinase with ADAMTS20 thrombospondin motifs 20
- P62937 Peptidyl-prolyl cis-trans isomerase A PPIA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21158620.1A EP3884949A1 (en) | 2012-06-08 | 2013-06-07 | Pulmonary delivery of mrna to non-lung target cells |
MX2014015041A MX2014015041A (en) | 2012-06-08 | 2013-06-07 | Pulmonary delivery of mrna to non-lung target cells. |
EP13800103.7A EP2858679B1 (en) | 2012-06-08 | 2013-06-07 | Pulmonary delivery of mrna to non-lung target cells |
JP2015516249A JP6561378B2 (en) | 2012-06-08 | 2013-06-07 | Transpulmonary delivery of mRNA to non-pulmonary target cells |
CA2876155A CA2876155C (en) | 2012-06-08 | 2013-06-07 | Pulmonary delivery of mrna to non-lung target cells |
US14/406,504 US10245229B2 (en) | 2012-06-08 | 2013-06-07 | Pulmonary delivery of mRNA to non-lung target cells |
ES13800103T ES2864878T3 (en) | 2012-06-08 | 2013-06-07 | Pulmonary RNA Delivery to Non-pulmonary Target Cells |
CN201380039829.6A CN104519915A (en) | 2012-06-08 | 2013-06-07 | Pulmonary delivery of mRNA to non-lung target cells |
EA201492055A EA201492055A1 (en) | 2012-06-08 | 2013-06-07 | INHALATIVE DELIVERY OF mRNA IN TIGHTNESS CELL TARGETS |
BR112014030677A BR112014030677A2 (en) | 2012-06-08 | 2013-06-07 | pulmonary distribution of mrna to non-pulmonary target cells |
AU2013271392A AU2013271392B2 (en) | 2012-06-08 | 2013-06-07 | Pulmonary delivery of mRNA to non-lung target cells |
HK15108982.6A HK1208352A1 (en) | 2012-06-08 | 2015-09-14 | Pulmonary delivery of mrna to non-lung target cells mrna |
HK15109129.8A HK1208618A1 (en) | 2012-06-08 | 2015-09-17 | Pulmonary delivery of mrna to non-lung target cells mrna |
AU2018203310A AU2018203310B2 (en) | 2012-06-08 | 2018-05-11 | PULMONARY DELIVERY OF mRNA TO NON-LUNG TARGET CELLS |
US16/258,191 US11090264B2 (en) | 2012-06-08 | 2019-01-25 | Pulmonary delivery of mRNA to non-lung target cells |
US17/389,016 US20220226236A1 (en) | 2012-06-08 | 2021-07-29 | Pulmonary Delivery of MRNA to Non-lung Target Cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261657452P | 2012-06-08 | 2012-06-08 | |
US61/657,452 | 2012-06-08 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/406,504 A-371-Of-International US10245229B2 (en) | 2012-06-08 | 2013-06-07 | Pulmonary delivery of mRNA to non-lung target cells |
US16/258,191 Division US11090264B2 (en) | 2012-06-08 | 2019-01-25 | Pulmonary delivery of mRNA to non-lung target cells |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013185069A1 true WO2013185069A1 (en) | 2013-12-12 |
Family
ID=49712697
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2013/044771 WO2013185069A1 (en) | 2012-06-08 | 2013-06-07 | Pulmonary delivery of mrna to non-lung target cells |
Country Status (12)
Country | Link |
---|---|
US (3) | US10245229B2 (en) |
EP (2) | EP2858679B1 (en) |
JP (3) | JP6561378B2 (en) |
CN (1) | CN104519915A (en) |
AU (2) | AU2013271392B2 (en) |
BR (1) | BR112014030677A2 (en) |
CA (1) | CA2876155C (en) |
EA (1) | EA201492055A1 (en) |
ES (1) | ES2864878T3 (en) |
HK (2) | HK1208352A1 (en) |
MX (1) | MX2014015041A (en) |
WO (1) | WO2013185069A1 (en) |
Cited By (132)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
WO2015011633A1 (en) * | 2013-07-23 | 2015-01-29 | Protiva Biotherapeutics, Inc. | Compositions and methods for delivering messenger rna |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
US8999380B2 (en) | 2012-04-02 | 2015-04-07 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
WO2015061500A1 (en) * | 2013-10-22 | 2015-04-30 | Shire Human Genetic Therapies, Inc. | Mrna therapy for argininosuccinate synthetase deficiency |
US9107886B2 (en) | 2012-04-02 | 2015-08-18 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding basic helix-loop-helix family member E41 |
WO2014153052A3 (en) * | 2013-03-14 | 2015-09-24 | Shire Human Genetic Therapies, Inc. | Cftr mrna compositions and related methods and uses |
EP2929035A1 (en) * | 2012-12-07 | 2015-10-14 | Shire Human Genetic Therapies, Inc. | Lipidic nanoparticles for mrna delivering |
US9186372B2 (en) | 2011-12-16 | 2015-11-17 | Moderna Therapeutics, Inc. | Split dose administration |
EP2830595A4 (en) * | 2012-03-29 | 2016-03-09 | Shire Human Genetic Therapies | Ionizable cationic lipids |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9308281B2 (en) | 2011-06-08 | 2016-04-12 | Shire Human Genetic Therapies, Inc. | MRNA therapy for Fabry disease |
US9334328B2 (en) | 2010-10-01 | 2016-05-10 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
WO2016090262A1 (en) | 2014-12-05 | 2016-06-09 | Shire Human Genetic Therapies, Inc. | Messenger rna therapy for treatment of articular disease |
EP3041948A1 (en) | 2014-11-10 | 2016-07-13 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules containing reduced uracil content and uses thereof |
US9428535B2 (en) | 2011-10-03 | 2016-08-30 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9522176B2 (en) | 2013-10-22 | 2016-12-20 | Shire Human Genetic Therapies, Inc. | MRNA therapy for phenylketonuria |
US9533047B2 (en) | 2011-03-31 | 2017-01-03 | Modernatx, Inc. | Delivery and formulation of engineered nucleic acids |
WO2017001570A2 (en) | 2015-06-30 | 2017-01-05 | Ethris Gmbh | Atp-binding cassette family coding polyribonucleotides and formulations thereof |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9597380B2 (en) | 2012-11-26 | 2017-03-21 | Modernatx, Inc. | Terminally modified RNA |
WO2017100562A1 (en) | 2015-12-09 | 2017-06-15 | Alexion Pharmaceuticals, Inc, | Modified mrna encoding a uridine diphopsphate glucuronosyl transferase and uses thereof |
WO2017127750A1 (en) | 2016-01-22 | 2017-07-27 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
WO2017180917A2 (en) | 2016-04-13 | 2017-10-19 | Modernatx, Inc. | Lipid compositions and their uses for intratumoral polynucleotide delivery |
WO2017201350A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding interleukin-12 (il12) and uses thereof |
US9850269B2 (en) | 2014-04-25 | 2017-12-26 | Translate Bio, Inc. | Methods for purification of messenger RNA |
US20180008680A1 (en) * | 2016-06-13 | 2018-01-11 | Rana Therapeutics, Inc. | Messenger RNA Therapy for the Treatment of Ornithine Transcarbamylase Deficiency |
US9872900B2 (en) | 2014-04-23 | 2018-01-23 | Modernatx, Inc. | Nucleic acid vaccines |
US9957499B2 (en) | 2013-03-14 | 2018-05-01 | Translate Bio, Inc. | Methods for purification of messenger RNA |
WO2018157133A1 (en) | 2017-02-27 | 2018-08-30 | Translate Bio, Inc. | Methods for purification of messenger rna |
WO2018157141A1 (en) | 2017-02-27 | 2018-08-30 | Translate Bio, Inc. | Methods for purification of messenger rna |
US10064935B2 (en) | 2015-10-22 | 2018-09-04 | Modernatx, Inc. | Human cytomegalovirus RNA vaccines |
US10064934B2 (en) | 2015-10-22 | 2018-09-04 | Modernatx, Inc. | Combination PIV3/hMPV RNA vaccines |
US10124055B2 (en) | 2015-10-22 | 2018-11-13 | Modernatx, Inc. | Zika virus RNA vaccines |
US10130649B2 (en) * | 2013-03-15 | 2018-11-20 | Translate Bio, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
WO2018231990A2 (en) | 2017-06-14 | 2018-12-20 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase |
WO2019018765A1 (en) | 2017-07-21 | 2019-01-24 | Modernatx, Inc. | Modified mrna encoding a propionyl-coa carboxylase and uses thereof |
WO2019023179A1 (en) | 2017-07-24 | 2019-01-31 | Modernatx, Inc. | Modified mrna encoding a glucose-6-phosphatase and uses thereof |
US10195156B2 (en) | 2015-12-22 | 2019-02-05 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
US10207010B2 (en) | 2015-12-10 | 2019-02-19 | Modernatx, Inc. | Compositions and methods for delivery of agents |
KR20190026670A (en) * | 2016-05-18 | 2019-03-13 | 모더나티엑스, 인크. | Polynucleotides encoding Relaxin |
WO2018236134A3 (en) * | 2017-06-21 | 2019-03-28 | Korea Research Institute Of Bioscience And Biotechnology | Method and kit for diagnosis of muscle weakness-related diseases using blood biomarker |
EP3364982A4 (en) * | 2015-10-22 | 2019-04-17 | ModernaTX, Inc. | Sexually transmitted disease vaccines |
US10266485B2 (en) | 2015-09-17 | 2019-04-23 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
US10273269B2 (en) | 2017-02-16 | 2019-04-30 | Modernatx, Inc. | High potency immunogenic zika virus compositions |
US10286086B2 (en) | 2014-06-19 | 2019-05-14 | Modernatx, Inc. | Alternative nucleic acid molecules and uses thereof |
US10323076B2 (en) | 2013-10-03 | 2019-06-18 | Modernatx, Inc. | Polynucleotides encoding low density lipoprotein receptor |
EP3365009A4 (en) * | 2015-10-22 | 2019-07-03 | ModernaTX, Inc. | Herpes simplex virus vaccine |
EP3365007A4 (en) * | 2015-10-22 | 2019-07-03 | ModernaTX, Inc. | Broad spectrum influenza virus vaccine |
EP3364980A4 (en) * | 2015-10-22 | 2019-07-10 | ModernaTX, Inc. | Nucleic acid vaccines for varicella zoster virus (vzv) |
WO2019148101A1 (en) | 2018-01-29 | 2019-08-01 | Modernatx, Inc. | Rsv rna vaccines |
EP3365008A4 (en) * | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | Respiratory syncytial virus vaccine |
US10385088B2 (en) | 2013-10-02 | 2019-08-20 | Modernatx, Inc. | Polynucleotide molecules and uses thereof |
US10407683B2 (en) | 2014-07-16 | 2019-09-10 | Modernatx, Inc. | Circular polynucleotides |
US10449244B2 (en) | 2015-07-21 | 2019-10-22 | Modernatx, Inc. | Zika RNA vaccines |
US10507183B2 (en) | 2011-06-08 | 2019-12-17 | Translate Bio, Inc. | Cleavable lipids |
WO2020023533A1 (en) * | 2018-07-23 | 2020-01-30 | Translate Bio, Inc. | Dry power formulations for messenger rna |
WO2020041793A1 (en) | 2018-08-24 | 2020-02-27 | Translate Bio, Inc. | Methods for purification of messenger rna |
US10576166B2 (en) | 2009-12-01 | 2020-03-03 | Translate Bio, Inc. | Liver specific delivery of messenger RNA |
US10590161B2 (en) | 2013-03-15 | 2020-03-17 | Modernatx, Inc. | Ion exchange purification of mRNA |
WO2020097509A1 (en) | 2018-11-08 | 2020-05-14 | Translate Bio, Inc. | Methods and compositions for messenger rna purification |
US10653767B2 (en) | 2017-09-14 | 2020-05-19 | Modernatx, Inc. | Zika virus MRNA vaccines |
US10695419B2 (en) | 2016-10-21 | 2020-06-30 | Modernatx, Inc. | Human cytomegalovirus vaccine |
US10815291B2 (en) | 2013-09-30 | 2020-10-27 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
CN111929441A (en) * | 2020-08-17 | 2020-11-13 | 南通大学附属医院 | Biomarker and kit used in lung cancer diagnosis and prognosis evaluation |
US10857105B2 (en) | 2017-03-15 | 2020-12-08 | MordernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
US10858647B2 (en) | 2013-03-15 | 2020-12-08 | Modernatx, Inc. | Removal of DNA fragments in mRNA production process |
CN112553328A (en) * | 2020-12-30 | 2021-03-26 | 浙江大学 | Product for detecting gene expression level and application thereof in preparation of major depressive disorder diagnosis tool |
WO2021072172A1 (en) * | 2019-10-09 | 2021-04-15 | Translate Bio, Inc. | Compositions, methods and uses of messenger rna |
EP2970456B1 (en) | 2013-03-14 | 2021-05-19 | Translate Bio, Inc. | Methods and compositions for delivering mrna coded antibodies |
US11027025B2 (en) | 2013-07-11 | 2021-06-08 | Modernatx, Inc. | Compositions comprising synthetic polynucleotides encoding CRISPR related proteins and synthetic sgRNAs and methods of use |
US11066355B2 (en) | 2019-09-19 | 2021-07-20 | Modernatx, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
WO2021154763A1 (en) | 2020-01-28 | 2021-08-05 | Modernatx, Inc. | Coronavirus rna vaccines |
WO2021159130A2 (en) | 2020-05-15 | 2021-08-12 | Modernatx, Inc. | Coronavirus rna vaccines and methods of use |
WO2021159040A2 (en) | 2020-02-07 | 2021-08-12 | Modernatx, Inc. | Sars-cov-2 mrna domain vaccines |
US11103578B2 (en) | 2016-12-08 | 2021-08-31 | Modernatx, Inc. | Respiratory virus nucleic acid vaccines |
WO2021222304A1 (en) | 2020-04-27 | 2021-11-04 | Modernatx, Inc. | Sars-cov-2 rna vaccines |
US11167043B2 (en) | 2017-12-20 | 2021-11-09 | Translate Bio, Inc. | Composition and methods for treatment of ornithine transcarbamylase deficiency |
US11173190B2 (en) | 2017-05-16 | 2021-11-16 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of codon-optimized mRNA encoding CFTR |
US11191849B2 (en) | 2016-06-30 | 2021-12-07 | Arbutus Biopharma Corporation | Compositions and methods for delivering messenger RNA |
US11203569B2 (en) | 2017-03-15 | 2021-12-21 | Modernatx, Inc. | Crystal forms of amino lipids |
EP3762495A4 (en) * | 2018-03-07 | 2021-12-22 | Icahn School of Medicine at Mount Sinai | Modrna encoding sphingolipid-metabolizing proteins |
US11253605B2 (en) | 2017-02-27 | 2022-02-22 | Translate Bio, Inc. | Codon-optimized CFTR MRNA |
US11254936B2 (en) | 2012-06-08 | 2022-02-22 | Translate Bio, Inc. | Nuclease resistant polynucleotides and uses thereof |
WO2022067010A1 (en) | 2020-09-25 | 2022-03-31 | Modernatx, Inc. | Multi-proline-substituted coronavirus spike protein vaccines |
US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
US11377470B2 (en) | 2013-03-15 | 2022-07-05 | Modernatx, Inc. | Ribonucleic acid purification |
WO2022150717A1 (en) | 2021-01-11 | 2022-07-14 | Modernatx, Inc. | Seasonal rna influenza virus vaccines |
WO2022155524A1 (en) | 2021-01-15 | 2022-07-21 | Modernatx, Inc. | Variant strain-based coronavirus vaccines |
WO2022155530A1 (en) | 2021-01-15 | 2022-07-21 | Modernatx, Inc. | Variant strain-based coronavirus vaccines |
EP4035659A1 (en) | 2016-11-29 | 2022-08-03 | PureTech LYT, Inc. | Exosomes for delivery of therapeutic agents |
US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
US11434486B2 (en) | 2015-09-17 | 2022-09-06 | Modernatx, Inc. | Polynucleotides containing a morpholino linker |
US11433027B2 (en) | 2015-05-20 | 2022-09-06 | Curevac Ag | Dry powder composition comprising long-chain RNA |
US11446250B2 (en) | 2015-04-17 | 2022-09-20 | Curevac Real Estate Gmbh | Lyophilization of RNA |
WO2022197624A1 (en) | 2021-03-15 | 2022-09-22 | Modernatx, Inc. | Therapeutic use of sars-cov-2 mrna domain vaccines |
US11464848B2 (en) | 2017-03-15 | 2022-10-11 | Modernatx, Inc. | Respiratory syncytial virus vaccine |
WO2022221440A1 (en) | 2021-04-14 | 2022-10-20 | Modernatx, Inc. | Influenza-coronavirus combination vaccines |
WO2022221335A1 (en) | 2021-04-13 | 2022-10-20 | Modernatx, Inc. | Respiratory virus combination vaccines |
US11497807B2 (en) | 2017-03-17 | 2022-11-15 | Modernatx, Inc. | Zoonotic disease RNA vaccines |
WO2022245888A1 (en) | 2021-05-19 | 2022-11-24 | Modernatx, Inc. | Seasonal flu rna vaccines and methods of use |
US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
US11534405B2 (en) | 2015-05-20 | 2022-12-27 | Curevac Ag | Dry powder composition comprising long-chain RNA |
US11576961B2 (en) | 2017-03-15 | 2023-02-14 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
WO2023025404A1 (en) | 2021-08-24 | 2023-03-02 | BioNTech SE | In vitro transcription technologies |
WO2023031394A1 (en) | 2021-09-03 | 2023-03-09 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
US11618893B2 (en) | 2018-06-29 | 2023-04-04 | Icahn School Of Medicine At Mount Sinai | Anc80 encoding sphingolipid-metabolizing proteins for mitigating disease-induced tissue damage |
WO2023069498A1 (en) | 2021-10-22 | 2023-04-27 | Senda Biosciences, Inc. | Mrna vaccine composition |
WO2023073228A1 (en) | 2021-10-29 | 2023-05-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
WO2023092069A1 (en) | 2021-11-18 | 2023-05-25 | Modernatx, Inc. | Sars-cov-2 mrna domain vaccines and methods of use |
WO2023096858A1 (en) | 2021-11-23 | 2023-06-01 | Senda Biosciences, Inc. | A bacteria-derived lipid composition and use thereof |
WO2023107999A2 (en) | 2021-12-08 | 2023-06-15 | Modernatx, Inc. | Herpes simplex virus mrna vaccines |
WO2023122080A1 (en) | 2021-12-20 | 2023-06-29 | Senda Biosciences, Inc. | Compositions comprising mrna and lipid reconstructed plant messenger packs |
WO2023144330A1 (en) | 2022-01-28 | 2023-08-03 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
US11744801B2 (en) | 2017-08-31 | 2023-09-05 | Modernatx, Inc. | Methods of making lipid nanoparticles |
WO2023196914A1 (en) | 2022-04-08 | 2023-10-12 | Modernatx, Inc. | Influenza nucleic acid compositions and uses thereof |
US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
US11801227B2 (en) | 2016-05-18 | 2023-10-31 | Modernatx, Inc. | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis |
EP4223306A3 (en) * | 2019-02-14 | 2023-11-29 | Ethris GmbH | Treatment of ciliopathies |
WO2023230481A1 (en) | 2022-05-24 | 2023-11-30 | Modernatx, Inc. | Orthopoxvirus vaccines |
WO2023227608A1 (en) | 2022-05-25 | 2023-11-30 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
RU2810732C1 (en) * | 2020-02-03 | 2023-12-28 | Хаплнсайенс Инк. | Composition containing hyaluronan/proteoglycan-binding protein 1 for prevention or treatment of lung diseases |
US11859215B2 (en) | 2017-11-22 | 2024-01-02 | Modernatx, Inc. | Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders |
WO2024015890A1 (en) | 2022-07-13 | 2024-01-18 | Modernatx, Inc. | Norovirus mrna vaccines |
WO2024050483A1 (en) | 2022-08-31 | 2024-03-07 | Modernatx, Inc. | Variant strain-based coronavirus vaccines and uses thereof |
DE202023106198U1 (en) | 2022-10-28 | 2024-03-21 | CureVac SE | Nucleic acid-based vaccine |
WO2024084089A1 (en) | 2022-10-21 | 2024-04-25 | BioNTech SE | Methods and uses associated with liquid compositions |
US11969506B2 (en) | 2017-03-15 | 2024-04-30 | Modernatx, Inc. | Lipid nanoparticle formulation |
WO2024102434A1 (en) | 2022-11-10 | 2024-05-16 | Senda Biosciences, Inc. | Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3294885B1 (en) | 2015-05-08 | 2020-07-01 | CureVac Real Estate GmbH | Method for producing rna |
CN107873055B (en) | 2015-05-29 | 2021-09-17 | 库瑞瓦格房地产有限公司 | Method for producing and purifying RNA comprising at least one tangential flow filtration step |
US10053693B2 (en) | 2016-01-19 | 2018-08-21 | Mubin I. Syed | Method for controlling obesity using minimally invasive means |
US10857209B2 (en) | 2016-02-12 | 2020-12-08 | Indiana University Research And Technology Corporation | Lysosomal acid lipase and PPAR gamma ligands as immune therapies for cancer treatment |
CA3024507A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding .alpha.-galactosidase a for the treatment of fabry disease |
EP3565605A1 (en) | 2017-01-03 | 2019-11-13 | ethris GmbH | Ornithine transcarbamylase coding polyribonucleotides and formulations thereof |
EP3568411B1 (en) * | 2017-01-13 | 2024-03-06 | Pietro P. Sanna | Methods and compositions for treating hpa hyperactivity |
MX2020006843A (en) * | 2017-12-27 | 2020-09-03 | Takeda Pharmaceuticals Co | Nucleic acid-containing lipid nano-particle and use thereof. |
CA3100995A1 (en) | 2018-05-10 | 2019-11-14 | The University Of Manchester | Methods for assessing macular degeneration |
JP7448488B2 (en) * | 2018-05-15 | 2024-03-12 | トランスレイト バイオ, インコーポレイテッド | Subcutaneous delivery of messenger RNA |
WO2020041783A1 (en) * | 2018-08-24 | 2020-02-27 | Flagship Pioneering Innovations Vi, Llc. | Modified plant messenger packs and uses thereof |
CN112805294A (en) | 2018-09-28 | 2021-05-14 | 胡桃钳医疗公司 | Tertiary aminolipidated cationic peptides for nucleic acid delivery |
SG11202101732WA (en) * | 2018-10-01 | 2021-03-30 | Univ Mainz Johannes Gutenberg | Rna particles comprising polysarcosine |
KR20210093232A (en) | 2018-10-09 | 2021-07-27 | 더 유니버시티 오브 브리티시 콜롬비아 | Compositions and systems and related methods comprising transfection competent vesicles free of organic solvent and detergent |
CN114615985A (en) * | 2019-09-11 | 2022-06-10 | 西奈山伊坎医学院 | Compositions comprising molecules that modify mRNA and methods of use thereof |
KR102166453B1 (en) * | 2020-02-03 | 2020-10-15 | 중앙대학교 산학협력단 | Composition for preventing or treating pulmonary diseases comprising hapln1 |
EP4214515A1 (en) | 2020-09-16 | 2023-07-26 | Complement Therapeutics Limited | Complementome assay |
TW202233232A (en) | 2020-11-06 | 2022-09-01 | 法商賽諾菲公司 | Lipid nanoparticles for delivering mrna vaccines |
US20240115500A1 (en) * | 2020-12-09 | 2024-04-11 | Aravasc Inc. | Polymeric micelle complexes of mrna or zwitterionic agents, and formulations and uses thereof |
KR20240005692A (en) * | 2021-03-22 | 2024-01-12 | 리코드 테라퓨틱스, 인크. | Compositions and methods for targeted delivery to cells |
CN115300609A (en) * | 2021-05-08 | 2022-11-08 | 西湖大学 | Use of hypoxia-inducible lipid droplet-associated protein (HIPDA) for preventing or treating hyperlipidemia-associated diseases |
GB202107586D0 (en) | 2021-05-27 | 2021-07-14 | Complement Therapeutics Ltd | Inhibitory nucleic acids for Factor H family proteins |
EP4355308A1 (en) | 2021-06-18 | 2024-04-24 | Sanofi | Multivalent influenza vaccines |
WO2023079507A1 (en) | 2021-11-05 | 2023-05-11 | Sanofi | Respiratory syncytial virus rna vaccine |
US20230310571A1 (en) | 2021-11-30 | 2023-10-05 | Sanofi Pasteur Inc. | Human metapneumovirus vaccines |
WO2023111262A1 (en) | 2021-12-17 | 2023-06-22 | Sanofi | Lyme disease rna vaccine |
GB202203627D0 (en) | 2022-03-16 | 2022-04-27 | Univ Manchester | Agents for treating complement-related disorders |
WO2023214082A2 (en) | 2022-05-06 | 2023-11-09 | Sanofi | Signal sequences for nucleic acid vaccines |
IL292957A (en) | 2022-05-11 | 2023-12-01 | Yeda res & development co ltd | Treatment of heart disease |
WO2024044108A1 (en) | 2022-08-22 | 2024-02-29 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Vaccines against coronaviruses |
GB202214445D0 (en) | 2022-09-30 | 2022-11-16 | Imp College Innovations Ltd | Gene therapy |
WO2024094876A1 (en) | 2022-11-04 | 2024-05-10 | Sanofi | Methods for messenger rna tailing |
WO2024094881A1 (en) | 2022-11-04 | 2024-05-10 | Sanofi | Respiratory syncytial virus rna vaccination |
Citations (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4373071A (en) | 1981-04-30 | 1983-02-08 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
US4401796A (en) | 1981-04-30 | 1983-08-30 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
US4415732A (en) | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
US5047524A (en) | 1988-12-21 | 1991-09-10 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
US5153319A (en) | 1986-03-31 | 1992-10-06 | University Patents, Inc. | Process for preparing polynucleotides |
US5171678A (en) | 1989-04-17 | 1992-12-15 | Centre National De La Recherche Scientifique | Lipopolyamines, their preparation and their use |
US5262530A (en) | 1988-12-21 | 1993-11-16 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
US5334761A (en) | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
US5700642A (en) | 1995-05-22 | 1997-12-23 | Sri International | Oligonucleotide sizing using immobilized cleavable primers |
WO1998010748A1 (en) * | 1996-09-13 | 1998-03-19 | The School Of Pharmacy | Liposomes |
US5744335A (en) | 1995-09-19 | 1998-04-28 | Mirus Corporation | Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein |
US5780014A (en) | 1995-04-14 | 1998-07-14 | Inhale Therapeutic Systems | Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin |
US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
US20020192651A1 (en) * | 1995-06-07 | 2002-12-19 | Jeffrey Wheeler | Method of preventing aggregation of a lipid: nucleic acid complex |
US20040224912A1 (en) * | 2003-05-07 | 2004-11-11 | Isis Pharmaceuticals Inc. | Modulation of PAI-1 mRNA-binding protein expression |
US20050158302A1 (en) * | 1998-02-27 | 2005-07-21 | General Hospital Corporation | Methods for diagnosing and treating autoimmune disease |
WO2005121348A1 (en) | 2004-06-07 | 2005-12-22 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering rna |
WO2006016097A2 (en) * | 2004-08-13 | 2006-02-16 | Ic Vec Limited | Vector comprising polymer modified sirna liposomes |
WO2008052770A2 (en) | 2006-10-31 | 2008-05-08 | Curevac Gmbh | (base-)modified rna for increasing the expression of a protein |
US20080286834A1 (en) | 2005-01-27 | 2008-11-20 | Robert Forgan Halenbeck | Leader Sequences For Directing Secretion of Polypeptides and Methods For Production Thereof |
US20090286852A1 (en) | 2005-08-23 | 2009-11-19 | Katalin Kariko | RNA containing modified nucleosides and methods of use thereof |
WO2010042877A1 (en) | 2008-10-09 | 2010-04-15 | Tekmira Pharmaceuticals Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
WO2010053572A2 (en) | 2008-11-07 | 2010-05-14 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
WO2010056403A1 (en) * | 2008-11-17 | 2010-05-20 | Enzon Pharmaceuticals, Inc. | Branched cationic lipids for nucleic acids delivery system |
WO2011068810A1 (en) | 2009-12-01 | 2011-06-09 | Shire Human Genetic Therapies | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
US20120027803A1 (en) | 2010-06-03 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
EP2459231A2 (en) | 2009-07-31 | 2012-06-06 | Ethris Gmbh | Rna with a combination of unmodified and modified nucleotides for protein expression |
WO2012170930A1 (en) | 2011-06-08 | 2012-12-13 | Shire Human Genetic Therapies, Inc | Lipid nanoparticle compositions and methods for mrna delivery |
WO2012170889A1 (en) | 2011-06-08 | 2012-12-13 | Shire Human Genetic Therapies, Inc. | Cleavable lipids |
Family Cites Families (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0465529B1 (en) | 1989-03-21 | 1998-04-29 | Vical, Inc. | Expression of exogenous polynucleotide sequences in a vertebrate |
DE69207603T2 (en) * | 1991-08-16 | 1996-09-12 | Vical Inc | COMPOSITION AND METHOD FOR TREATING CYSTIC FIBROSE |
US5858784A (en) * | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
US5965434A (en) | 1994-12-29 | 1999-10-12 | Wolff; Jon A. | Amphipathic PH sensitive compounds and delivery systems for delivering biologically active compounds |
US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
US5705385A (en) | 1995-06-07 | 1998-01-06 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
EP1489184A1 (en) * | 1995-06-07 | 2004-12-22 | Inex Pharmaceutical Corp. | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
US6734171B1 (en) | 1997-10-10 | 2004-05-11 | Inex Pharmaceuticals Corp. | Methods for encapsulating nucleic acids in lipid bilayers |
CA2368185A1 (en) | 1999-04-02 | 2000-10-12 | Research Development Foundation | Polyethyleneimine:dna formulations for aerosol delivery |
CA2491164C (en) | 2002-06-28 | 2012-05-08 | Cory Giesbrecht | Method and apparatus for producing liposomes |
JP2006517962A (en) * | 2003-01-18 | 2006-08-03 | チルドレンズ ホスピタル メディカル センター | Regulation of genes induced by allergens |
NZ592917A (en) | 2003-09-15 | 2012-12-21 | Protiva Biotherapeutics Inc | Stable polyethyleneglycol (PEG) dialkyloxypropyl (DAA) lipid conjugates |
EP1781593B1 (en) | 2004-06-07 | 2011-12-14 | Protiva Biotherapeutics Inc. | Cationic lipids and methods of use |
JP2008509205A (en) * | 2004-08-13 | 2008-03-27 | アイシー・ベック・リミテッド | Vector containing polymer-modified siRNA liposomes |
DE102004042546A1 (en) | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Combination therapy for immune stimulation |
US8101741B2 (en) | 2005-11-02 | 2012-01-24 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
WO2009046739A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
WO2009073809A2 (en) | 2007-12-04 | 2009-06-11 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
ES2535419T3 (en) | 2007-12-27 | 2015-05-11 | Protiva Biotherapeutics Inc. | Polo kinase expression silencing using interfering RNA |
US20110097720A1 (en) | 2008-01-02 | 2011-04-28 | Alnylam Pharmaceuticals, Inc. | Screening method for selected amino lipid-containing compositions |
WO2009126933A2 (en) | 2008-04-11 | 2009-10-15 | Alnylam Pharmaceuticals, Inc. | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
DK2279254T3 (en) | 2008-04-15 | 2017-09-18 | Protiva Biotherapeutics Inc | PRESENT UNKNOWN LIPID FORMS FOR NUCLEIC ACID ADMINISTRATION |
DE102008001783A1 (en) | 2008-05-15 | 2009-11-19 | Deere & Company, Moline | Measuring arrangement for determining the contents of a sample taken from a crop stream |
WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
MX359674B (en) | 2008-11-10 | 2018-10-05 | Alnylam Pharmaceuticals Inc | Novel lipids and compositions for the delivery of therapeutics. |
US9023820B2 (en) | 2009-01-26 | 2015-05-05 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing apolipoprotein C-III expression |
WO2010110314A1 (en) * | 2009-03-27 | 2010-09-30 | 協和発酵キリン株式会社 | Therapeutic agent for pulmonary hypertension comprising nucleic acid |
EP2421506B1 (en) | 2009-04-22 | 2015-08-19 | Emory University | Nanocarrier therapy for treating invasive tumors |
JP5769701B2 (en) | 2009-05-05 | 2015-08-26 | テクミラ ファーマシューティカルズ コーポレイションTekmira Pharmaceuticals Corporation | Lipid composition |
KR102205886B1 (en) | 2009-06-10 | 2021-01-21 | 알닐람 파마슈티칼스 인코포레이티드 | Improved lipid formulation |
WO2010147992A1 (en) | 2009-06-15 | 2010-12-23 | Alnylam Pharmaceuticals, Inc. | Methods for increasing efficacy of lipid formulated sirna |
WO2011000108A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing apolipoprotein b |
WO2011000106A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Improved cationic lipids and methods for the delivery of therapeutic agents |
US9018187B2 (en) | 2009-07-01 | 2015-04-28 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
US8716464B2 (en) | 2009-07-20 | 2014-05-06 | Thomas W. Geisbert | Compositions and methods for silencing Ebola virus gene expression |
KR102505097B1 (en) | 2009-12-07 | 2023-03-02 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | Rna preparations comprising purified modified rna for reprogramming cells |
US20130017223A1 (en) | 2009-12-18 | 2013-01-17 | The University Of British Columbia | Methods and compositions for delivery of nucleic acids |
EP2569276B1 (en) | 2010-05-12 | 2021-02-24 | Arbutus Biopharma Corporation | Novel cationic lipids and methods of use thereof |
US9006417B2 (en) | 2010-06-30 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
PL3243526T3 (en) | 2010-07-06 | 2020-05-18 | Glaxosmithkline Biologicals S.A. | Delivery of rna to trigger multiple immune pathways |
MX2013000164A (en) | 2010-07-06 | 2013-03-05 | Novartis Ag | Liposomes with lipids having an advantageous pka- value for rna delivery. |
CN103052400B (en) | 2010-07-06 | 2016-11-16 | 诺华股份有限公司 | The viral sample delivery of particles of self replication RNA molecule |
US9770463B2 (en) * | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
US20130323269A1 (en) | 2010-07-30 | 2013-12-05 | Muthiah Manoharan | Methods and compositions for delivery of active agents |
WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
DE19177059T1 (en) | 2010-10-01 | 2021-10-07 | Modernatx, Inc. | RIBONUCLEIC ACID CONTAINING N1-METHYL-PSEUDOURACILE AND USES |
WO2012075040A2 (en) | 2010-11-30 | 2012-06-07 | Shire Human Genetic Therapies, Inc. | mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES |
WO2012113413A1 (en) | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
DE12722942T1 (en) | 2011-03-31 | 2021-09-30 | Modernatx, Inc. | RELEASE AND FORMULATION OF MANIPULATED NUCLEIC ACIDS |
AU2012255913A1 (en) | 2011-05-17 | 2013-11-21 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof for non-human vertebrates |
WO2013039861A2 (en) | 2011-09-12 | 2013-03-21 | modeRNA Therapeutics | Engineered nucleic acids and methods of use thereof |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EP2755986A4 (en) | 2011-09-12 | 2015-05-20 | Moderna Therapeutics Inc | Engineered nucleic acids and methods of use thereof |
KR20140097143A (en) | 2011-10-05 | 2014-08-06 | 프로티바 바이오쎄라퓨틱스, 인코포레이티드 | Compositions and methods for silencing aldehyde dehydrogenase |
US20140378538A1 (en) | 2011-12-14 | 2014-12-25 | Moderma Therapeutics, Inc. | Methods of responding to a biothreat |
EP2791159A4 (en) | 2011-12-14 | 2015-10-14 | Moderna Therapeutics Inc | Modified nucleic acids, and acute care uses thereof |
MX2014007233A (en) | 2011-12-16 | 2015-02-04 | Moderna Therapeutics Inc | Modified nucleoside, nucleotide, and nucleic acid compositions. |
CN104968354A (en) | 2011-12-21 | 2015-10-07 | 现代治疗公司 | Methods of increasing the viability or longevity of an organ or organ explant |
US20140371302A1 (en) | 2011-12-29 | 2014-12-18 | Modema Therapeutics, Inc. | Modified mrnas encoding cell-penetrating polypeptides |
WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
KR20220045089A (en) | 2012-02-24 | 2022-04-12 | 아뷰터스 바이오파마 코포레이션 | Trialkyl cationic lipids and methods of use thereof |
DK2830595T3 (en) * | 2012-03-29 | 2019-12-02 | Translate Bio Inc | IONIZABLE CATIONIC LIPIDS |
EP2834259A4 (en) | 2012-04-02 | 2016-08-24 | Moderna Therapeutics Inc | Modified polynucleotides |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US20140275229A1 (en) | 2012-04-02 | 2014-09-18 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding udp glucuronosyltransferase 1 family, polypeptide a1 |
CA2868391A1 (en) | 2012-04-02 | 2013-10-10 | Stephane Bancel | Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same |
US20150050354A1 (en) | 2012-04-02 | 2015-02-19 | Moderna Therapeutics, Inc. | Modified polynucleotides for the treatment of otic diseases and conditions |
US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
CA2892529C (en) | 2012-11-26 | 2023-04-25 | Moderna Therapeutics, Inc. | Terminally modified rna |
US20150366997A1 (en) | 2012-12-07 | 2015-12-24 | Shire Human Genetics Therapies, Inc. | COMPOSITIONS AND METHODS FOR mRNA DELIVERY |
WO2014093574A1 (en) | 2012-12-13 | 2014-06-19 | Moderna Therapeutics, Inc. | Modified polynucleotides for altering cell phenotype |
EP2931319B1 (en) | 2012-12-13 | 2019-08-21 | ModernaTX, Inc. | Modified nucleic acid molecules and uses thereof |
JP2016504050A (en) | 2013-01-17 | 2016-02-12 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | Signal sensor polynucleotide for modification of cell phenotype |
WO2014158795A1 (en) | 2013-03-12 | 2014-10-02 | Moderna Therapeutics, Inc. | Diagnosis and treatment of fibrosis |
US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
WO2014144039A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Characterization of mrna molecules |
EP2983804A4 (en) | 2013-03-15 | 2017-03-01 | Moderna Therapeutics, Inc. | Ion exchange purification of mrna |
US10077439B2 (en) | 2013-03-15 | 2018-09-18 | Modernatx, Inc. | Removal of DNA fragments in mRNA production process |
WO2014152031A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Ribonucleic acid purification |
WO2014144711A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Analysis of mrna heterogeneity and stability |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
EP3578663A1 (en) | 2013-03-15 | 2019-12-11 | ModernaTX, Inc. | Manufacturing methods for production of rna transcripts |
JP7019233B2 (en) | 2013-07-11 | 2022-02-15 | モデルナティエックス インコーポレイテッド | Compositions and Methods of Use Containing Synthetic polynucleotides and Synthetic sgRNAs Encoding CRISPR-Related Proteins |
US20160151284A1 (en) | 2013-07-23 | 2016-06-02 | Protiva Biotherapeutics, Inc. | Compositions and methods for delivering messenger rna |
EP3041934A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
EP3041938A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Circular polynucleotides |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
US20160264614A1 (en) | 2013-10-02 | 2016-09-15 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
EP3052511A4 (en) | 2013-10-02 | 2017-05-31 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
AU2014337156A1 (en) | 2013-10-18 | 2016-05-12 | Modernatx, Inc. | Compositions and methods for tolerizing cellular systems |
EP3076994A4 (en) | 2013-12-06 | 2017-06-07 | Modernatx, Inc. | Targeted adaptive vaccines |
US20150167017A1 (en) | 2013-12-13 | 2015-06-18 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules and uses thereof |
DK3090053T3 (en) | 2013-12-30 | 2019-02-25 | Curevac Ag | Artificial nucleic acid molecules |
US20170002060A1 (en) | 2014-01-08 | 2017-01-05 | Moderna Therapeutics, Inc. | Polynucleotides for the in vivo production of antibodies |
WO2015135558A1 (en) | 2014-03-12 | 2015-09-17 | Curevac Gmbh | Combination of vaccination and ox40 agonists |
RU2746406C2 (en) | 2014-04-23 | 2021-04-13 | МОДЕРНАТиЭкс, ИНК. | Vaccines based on nucleic acids |
EP3201338B1 (en) | 2014-10-02 | 2021-11-03 | Arbutus Biopharma Corporation | Compositions and methods for silencing hepatitis b virus gene expression |
WO2016071857A1 (en) | 2014-11-07 | 2016-05-12 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing ebola virus expression |
US20170362627A1 (en) | 2014-11-10 | 2017-12-21 | Modernatx, Inc. | Multiparametric nucleic acid optimization |
EP3041948B1 (en) | 2014-11-10 | 2019-01-09 | Modernatx, Inc. | Alternative nucleic acid molecules containing reduced uracil content and uses thereof |
WO2016118724A1 (en) | 2015-01-21 | 2016-07-28 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
WO2016118725A1 (en) | 2015-01-23 | 2016-07-28 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
US20180245077A1 (en) | 2015-03-20 | 2018-08-30 | Protiva Biotherapeutics, Inc. | Compositions and methods for treating hypertriglyceridemia |
WO2016164762A1 (en) | 2015-04-08 | 2016-10-13 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same |
WO2016183366A2 (en) | 2015-05-12 | 2016-11-17 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing expression of hepatitis d virus rna |
US10626393B2 (en) | 2015-06-04 | 2020-04-21 | Arbutus Biopharma Corporation | Delivering CRISPR therapeutics with lipid nanoparticles |
US20180245074A1 (en) | 2015-06-04 | 2018-08-30 | Protiva Biotherapeutics, Inc. | Treating hepatitis b virus infection using crispr |
EP3307305A4 (en) | 2015-06-10 | 2019-05-22 | Modernatx, Inc. | Targeted adaptive vaccines |
US20180208932A1 (en) | 2015-07-29 | 2018-07-26 | Arbutus Biopharma Corporation | Compositions and methods for silencing hepatitis b virus gene expression |
-
2013
- 2013-06-07 EP EP13800103.7A patent/EP2858679B1/en active Active
- 2013-06-07 AU AU2013271392A patent/AU2013271392B2/en active Active
- 2013-06-07 MX MX2014015041A patent/MX2014015041A/en unknown
- 2013-06-07 EP EP21158620.1A patent/EP3884949A1/en active Pending
- 2013-06-07 CN CN201380039829.6A patent/CN104519915A/en active Pending
- 2013-06-07 US US14/406,504 patent/US10245229B2/en active Active
- 2013-06-07 ES ES13800103T patent/ES2864878T3/en active Active
- 2013-06-07 EA EA201492055A patent/EA201492055A1/en unknown
- 2013-06-07 WO PCT/US2013/044771 patent/WO2013185069A1/en active Application Filing
- 2013-06-07 BR BR112014030677A patent/BR112014030677A2/en not_active Application Discontinuation
- 2013-06-07 CA CA2876155A patent/CA2876155C/en active Active
- 2013-06-07 JP JP2015516249A patent/JP6561378B2/en active Active
-
2015
- 2015-09-14 HK HK15108982.6A patent/HK1208352A1/en unknown
- 2015-09-17 HK HK15109129.8A patent/HK1208618A1/en unknown
-
2017
- 2017-09-04 JP JP2017169486A patent/JP2017206567A/en active Pending
-
2018
- 2018-05-11 AU AU2018203310A patent/AU2018203310B2/en active Active
-
2019
- 2019-01-25 US US16/258,191 patent/US11090264B2/en active Active
- 2019-02-04 JP JP2019017747A patent/JP6913699B2/en active Active
-
2021
- 2021-07-29 US US17/389,016 patent/US20220226236A1/en active Pending
Patent Citations (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
US4415732A (en) | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
US4373071A (en) | 1981-04-30 | 1983-02-08 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
US4401796A (en) | 1981-04-30 | 1983-08-30 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5153319A (en) | 1986-03-31 | 1992-10-06 | University Patents, Inc. | Process for preparing polynucleotides |
US5047524A (en) | 1988-12-21 | 1991-09-10 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
US5262530A (en) | 1988-12-21 | 1993-11-16 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
US5171678A (en) | 1989-04-17 | 1992-12-15 | Centre National De La Recherche Scientifique | Lipopolyamines, their preparation and their use |
US5334761A (en) | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
US5780014A (en) | 1995-04-14 | 1998-07-14 | Inhale Therapeutic Systems | Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin |
US5700642A (en) | 1995-05-22 | 1997-12-23 | Sri International | Oligonucleotide sizing using immobilized cleavable primers |
US20020192651A1 (en) * | 1995-06-07 | 2002-12-19 | Jeffrey Wheeler | Method of preventing aggregation of a lipid: nucleic acid complex |
US5744335A (en) | 1995-09-19 | 1998-04-28 | Mirus Corporation | Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein |
WO1998010748A1 (en) * | 1996-09-13 | 1998-03-19 | The School Of Pharmacy | Liposomes |
US20050158302A1 (en) * | 1998-02-27 | 2005-07-21 | General Hospital Corporation | Methods for diagnosing and treating autoimmune disease |
US20040224912A1 (en) * | 2003-05-07 | 2004-11-11 | Isis Pharmaceuticals Inc. | Modulation of PAI-1 mRNA-binding protein expression |
WO2005121348A1 (en) | 2004-06-07 | 2005-12-22 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering rna |
WO2006016097A2 (en) * | 2004-08-13 | 2006-02-16 | Ic Vec Limited | Vector comprising polymer modified sirna liposomes |
US20080286834A1 (en) | 2005-01-27 | 2008-11-20 | Robert Forgan Halenbeck | Leader Sequences For Directing Secretion of Polypeptides and Methods For Production Thereof |
US20090286852A1 (en) | 2005-08-23 | 2009-11-19 | Katalin Kariko | RNA containing modified nucleosides and methods of use thereof |
WO2008052770A2 (en) | 2006-10-31 | 2008-05-08 | Curevac Gmbh | (base-)modified rna for increasing the expression of a protein |
WO2010042877A1 (en) | 2008-10-09 | 2010-04-15 | Tekmira Pharmaceuticals Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
WO2010053572A2 (en) | 2008-11-07 | 2010-05-14 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
WO2010056403A1 (en) * | 2008-11-17 | 2010-05-20 | Enzon Pharmaceuticals, Inc. | Branched cationic lipids for nucleic acids delivery system |
EP2459231A2 (en) | 2009-07-31 | 2012-06-06 | Ethris Gmbh | Rna with a combination of unmodified and modified nucleotides for protein expression |
WO2011068810A1 (en) | 2009-12-01 | 2011-06-09 | Shire Human Genetic Therapies | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
US20110244026A1 (en) * | 2009-12-01 | 2011-10-06 | Braydon Charles Guild | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
US20120027803A1 (en) | 2010-06-03 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
WO2012170930A1 (en) | 2011-06-08 | 2012-12-13 | Shire Human Genetic Therapies, Inc | Lipid nanoparticle compositions and methods for mrna delivery |
WO2012170889A1 (en) | 2011-06-08 | 2012-12-13 | Shire Human Genetic Therapies, Inc. | Cleavable lipids |
Non-Patent Citations (24)
Title |
---|
ANDRIES ET AL., MOLECULAR PHARMACEUTICS, vol. 9, 2012, pages 2136 - 2145 |
BEHR ET AL., PROC. NAT.'L ACAD. SCI., vol. 86, 1989, pages 6982 |
DRUMMOND ET AL., PHARMACOL. REV., vol. 51, 1999, pages 691 - 743 |
FEIGNER ET AL., PROC. NAT'L ACAD. SCI., vol. 84, 1987, pages 7413 |
G. TAVERNIER ET AL., J. CONTROLLED RELEASE, vol. 150, 2011, pages 238 - 247 |
GAO ET AL., BIOCHEM. BIOPHYS. RES. COMM., vol. 179, 1991, pages 280 |
HEYES, J. ET AL., J CONTROLLED RELEASE, vol. 107, 2005, pages 276 - 287 |
HEYES, J.PALMER, L.BREMNER, K.MACLACHLAN, I.: "Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids", J. CONTR. REL., vol. 107, 2005, pages 276 - 287, XP008157522, doi:10.1016/j.jconrel.2005.06.014 |
KLIBANOV ET AL., FEBS LETTERS, vol. 268, no. 1, 1990, pages 235 - 237 |
KORMANN ET AL., NATURE BIOTECHNOLOGY, vol. 29, no. 2, 2011, pages 154 - 157 |
LAM ET AL.: "Pulmonary delivery of therapeutic siRNA", ADVANCED DRUG DELIVERY REVIEWS., vol. 64, 26 February 2011 (2011-02-26), pages 1 - 15, XP028908210 * |
LASIC ET AL., FEBS LETT., vol. 312, 1992, pages 255 - 258 |
LASIC, TRENDS BIOTECHNOL., vol. 16, 1998, pages 307 - 321 |
LOVE, K.T. ET AL.: "Lipid-like materials for low-dose in vivo gene silencing", PNAS, vol. 107, 2010, pages 1864 - 1869, XP055077922, doi:10.1073/pnas.0910603106 |
LUBKE ET AL.: "Proteomics of the Lysosome", BIOCHIM BIOPHYS ACTA, vol. 1793, 2009, pages 625 - 635, XP026073291, doi:10.1016/j.bbamcr.2008.09.018 |
MORRISSEY, DV. ET AL., NAT. BIOTECHNOL., vol. 23, no. 8, 2005, pages 1003 - 1007 |
SCHREIER.: "The new frontier: gene and oligonucleotide therapy.", PHARMACEUTICA ACTA HELVETIAE., vol. 68, January 1994 (1994-01-01), pages 145 - 159, XP023803513 * |
See also references of EP2858679A4 |
SEMPLE, S.C. ET AL.: "Rational Design of Cationic Lipids for siRNA Delivery", NATURE BIOTECH., vol. 28, 2010, pages 172 - 176 |
SMOLA ET AL.: "Nanocarriers as pulmonary drug deliverysystems to treat and to diagnose respiratory and non respiratory diseases", INTERNATIONAL JOURNAL OF NANOMEDICINE, vol. 3, no. 1, March 2008 (2008-03-01), pages 1 - 19, XP002476425 * |
TEREBESI JKWOK KYRICE KG, ANAL BIOCHEM., vol. 263, no. 1, 1 October 1998 (1998-10-01), pages 120 - 3 |
WOLF ET AL., BIOTECHNIQUES, vol. 23, 1997, pages 139 |
X. SU ET AL., MOL. PHARMACEUTICS, vol. 8, 2011, pages 774 - 787 |
ZHAO ET AL.: "Non-Vrial Gene Therapy", vol. 13, 2011, INTECH PUBLISHING, article "Cationic Liposomes in Different Structural Levels for Gene Delivery", pages: 293 - 318 |
Cited By (265)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10576166B2 (en) | 2009-12-01 | 2020-03-03 | Translate Bio, Inc. | Liver specific delivery of messenger RNA |
US9447164B2 (en) | 2010-08-06 | 2016-09-20 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9937233B2 (en) | 2010-08-06 | 2018-04-10 | Modernatx, Inc. | Engineered nucleic acids and methods of use thereof |
US9181319B2 (en) | 2010-08-06 | 2015-11-10 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US10064959B2 (en) | 2010-10-01 | 2018-09-04 | Modernatx, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US9334328B2 (en) | 2010-10-01 | 2016-05-10 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US9657295B2 (en) | 2010-10-01 | 2017-05-23 | Modernatx, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US9950068B2 (en) | 2011-03-31 | 2018-04-24 | Modernatx, Inc. | Delivery and formulation of engineered nucleic acids |
US9533047B2 (en) | 2011-03-31 | 2017-01-03 | Modernatx, Inc. | Delivery and formulation of engineered nucleic acids |
US10507183B2 (en) | 2011-06-08 | 2019-12-17 | Translate Bio, Inc. | Cleavable lipids |
US10413618B2 (en) | 2011-06-08 | 2019-09-17 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mRNA delivery |
US11951181B2 (en) | 2011-06-08 | 2024-04-09 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mRNA delivery |
US10702478B2 (en) | 2011-06-08 | 2020-07-07 | Translate Bio, Inc. | Cleavable lipids |
US10238754B2 (en) | 2011-06-08 | 2019-03-26 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for MRNA delivery |
US11052159B2 (en) | 2011-06-08 | 2021-07-06 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mRNA delivery |
US10350303B1 (en) | 2011-06-08 | 2019-07-16 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mRNA delivery |
US9597413B2 (en) | 2011-06-08 | 2017-03-21 | Shire Human Genetic Therapies, Inc. | Pulmonary delivery of mRNA |
US11185595B2 (en) | 2011-06-08 | 2021-11-30 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mRNA delivery |
US11234936B2 (en) | 2011-06-08 | 2022-02-01 | Translate Bio, Inc. | Cleavable lipids |
US11951180B2 (en) | 2011-06-08 | 2024-04-09 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for MRNA delivery |
US10507249B2 (en) | 2011-06-08 | 2019-12-17 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mRNA delivery |
US11291734B2 (en) | 2011-06-08 | 2022-04-05 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mRNA delivery |
US11338044B2 (en) | 2011-06-08 | 2022-05-24 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mRNA delivery |
US11951179B2 (en) | 2011-06-08 | 2024-04-09 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for MRNA delivery |
US10888626B2 (en) | 2011-06-08 | 2021-01-12 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mRNA delivery |
US9308281B2 (en) | 2011-06-08 | 2016-04-12 | Shire Human Genetic Therapies, Inc. | MRNA therapy for Fabry disease |
US11547764B2 (en) | 2011-06-08 | 2023-01-10 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for MRNA delivery |
US11730825B2 (en) | 2011-06-08 | 2023-08-22 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mRNA delivery |
US10751386B2 (en) | 2011-09-12 | 2020-08-25 | Modernatx, Inc. | Engineered nucleic acids and methods of use thereof |
US10022425B2 (en) | 2011-09-12 | 2018-07-17 | Modernatx, Inc. | Engineered nucleic acids and methods of use thereof |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9428535B2 (en) | 2011-10-03 | 2016-08-30 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US9295689B2 (en) | 2011-12-16 | 2016-03-29 | Moderna Therapeutics, Inc. | Formulation and delivery of PLGA microspheres |
US9186372B2 (en) | 2011-12-16 | 2015-11-17 | Moderna Therapeutics, Inc. | Split dose administration |
US9271996B2 (en) | 2011-12-16 | 2016-03-01 | Moderna Therapeutics, Inc. | Formulation and delivery of PLGA microspheres |
EP2830595A4 (en) * | 2012-03-29 | 2016-03-09 | Shire Human Genetic Therapies | Ionizable cationic lipids |
US10065919B2 (en) | 2012-03-29 | 2018-09-04 | Translate Bio, Inc. | Ionizable cationic lipids |
US9546128B2 (en) | 2012-03-29 | 2017-01-17 | Shire Human Genetic Therapies, Inc. | Ionizable cationic lipids |
US10766852B2 (en) | 2012-03-29 | 2020-09-08 | Translate Bio, Inc. | Ionizable cationic lipids |
US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
US9107886B2 (en) | 2012-04-02 | 2015-08-18 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding basic helix-loop-helix family member E41 |
US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9587003B2 (en) | 2012-04-02 | 2017-03-07 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
US8999380B2 (en) | 2012-04-02 | 2015-04-07 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
US9050297B2 (en) | 2012-04-02 | 2015-06-09 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding aryl hydrocarbon receptor nuclear translocator |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9675668B2 (en) | 2012-04-02 | 2017-06-13 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding hepatitis A virus cellular receptor 2 |
US9301993B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding apoptosis inducing factor 1 |
US9061059B2 (en) | 2012-04-02 | 2015-06-23 | Moderna Therapeutics, Inc. | Modified polynucleotides for treating protein deficiency |
US9089604B2 (en) | 2012-04-02 | 2015-07-28 | Moderna Therapeutics, Inc. | Modified polynucleotides for treating galactosylceramidase protein deficiency |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9782462B2 (en) | 2012-04-02 | 2017-10-10 | Modernatx, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
US9095552B2 (en) | 2012-04-02 | 2015-08-04 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding copper metabolism (MURR1) domain containing 1 |
US9814760B2 (en) | 2012-04-02 | 2017-11-14 | Modernatx, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
US9114113B2 (en) | 2012-04-02 | 2015-08-25 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding citeD4 |
US9827332B2 (en) | 2012-04-02 | 2017-11-28 | Modernatx, Inc. | Modified polynucleotides for the production of proteins |
US9828416B2 (en) | 2012-04-02 | 2017-11-28 | Modernatx, Inc. | Modified polynucleotides for the production of secreted proteins |
US9255129B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding SIAH E3 ubiquitin protein ligase 1 |
US9149506B2 (en) | 2012-04-02 | 2015-10-06 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding septin-4 |
US9233141B2 (en) | 2012-04-02 | 2016-01-12 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
US9220755B2 (en) | 2012-04-02 | 2015-12-29 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders |
US9192651B2 (en) | 2012-04-02 | 2015-11-24 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
US9221891B2 (en) | 2012-04-02 | 2015-12-29 | Moderna Therapeutics, Inc. | In vivo production of proteins |
US9216205B2 (en) | 2012-04-02 | 2015-12-22 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding granulysin |
US9220792B2 (en) | 2012-04-02 | 2015-12-29 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding aquaporin-5 |
US11254936B2 (en) | 2012-06-08 | 2022-02-22 | Translate Bio, Inc. | Nuclease resistant polynucleotides and uses thereof |
US9597380B2 (en) | 2012-11-26 | 2017-03-21 | Modernatx, Inc. | Terminally modified RNA |
EP2929035A1 (en) * | 2012-12-07 | 2015-10-14 | Shire Human Genetic Therapies, Inc. | Lipidic nanoparticles for mrna delivering |
EP3628335A1 (en) * | 2012-12-07 | 2020-04-01 | Translate Bio, Inc. | Lipidic nanoparticles for mrna delivery in the lungs |
WO2014153052A3 (en) * | 2013-03-14 | 2015-09-24 | Shire Human Genetic Therapies, Inc. | Cftr mrna compositions and related methods and uses |
EA037922B1 (en) * | 2013-03-14 | 2021-06-07 | Шир Хьюман Дженетик Терапис, Инк. | CFTR mRNA AND COMPOSITIONS FOR TREATING CYSTIC FIBROSIS IN A MAMMAL |
EP2970456B1 (en) | 2013-03-14 | 2021-05-19 | Translate Bio, Inc. | Methods and compositions for delivering mrna coded antibodies |
US10420791B2 (en) | 2013-03-14 | 2019-09-24 | Translate Bio, Inc. | CFTR MRNA compositions and related methods and uses |
US11510937B2 (en) | 2013-03-14 | 2022-11-29 | Translate Bio, Inc. | CFTR MRNA compositions and related methods and uses |
US10876104B2 (en) | 2013-03-14 | 2020-12-29 | Translate Bio, Inc. | Methods for purification of messenger RNA |
US9713626B2 (en) | 2013-03-14 | 2017-07-25 | Rana Therapeutics, Inc. | CFTR mRNA compositions and related methods and uses |
US11692189B2 (en) | 2013-03-14 | 2023-07-04 | Translate Bio, Inc. | Methods for purification of messenger RNA |
EP3446712A1 (en) * | 2013-03-14 | 2019-02-27 | Translate Bio Ma, Inc. | Cftr mrna compositions and related methods and uses |
US9181321B2 (en) | 2013-03-14 | 2015-11-10 | Shire Human Genetic Therapies, Inc. | CFTR mRNA compositions and related methods and uses |
US9957499B2 (en) | 2013-03-14 | 2018-05-01 | Translate Bio, Inc. | Methods for purification of messenger RNA |
US11820977B2 (en) | 2013-03-14 | 2023-11-21 | Translate Bio, Inc. | Methods for purification of messenger RNA |
US11377470B2 (en) | 2013-03-15 | 2022-07-05 | Modernatx, Inc. | Ribonucleic acid purification |
US11845772B2 (en) | 2013-03-15 | 2023-12-19 | Modernatx, Inc. | Ribonucleic acid purification |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
US10590161B2 (en) | 2013-03-15 | 2020-03-17 | Modernatx, Inc. | Ion exchange purification of mRNA |
US10858647B2 (en) | 2013-03-15 | 2020-12-08 | Modernatx, Inc. | Removal of DNA fragments in mRNA production process |
US10130649B2 (en) * | 2013-03-15 | 2018-11-20 | Translate Bio, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
US20200390797A1 (en) * | 2013-03-15 | 2020-12-17 | Translate Bio, Inc. | Synergistic Enhancement of the Delivery of Nucleic Acids via Blended Formulations |
US10646504B2 (en) | 2013-03-15 | 2020-05-12 | Translate Bio, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
US11027025B2 (en) | 2013-07-11 | 2021-06-08 | Modernatx, Inc. | Compositions comprising synthetic polynucleotides encoding CRISPR related proteins and synthetic sgRNAs and methods of use |
JP2016525146A (en) * | 2013-07-23 | 2016-08-22 | プロティバ バイオセラピューティクス インコーポレイテッド | Compositions and methods for delivering messenger RNA |
WO2015011633A1 (en) * | 2013-07-23 | 2015-01-29 | Protiva Biotherapeutics, Inc. | Compositions and methods for delivering messenger rna |
US10815291B2 (en) | 2013-09-30 | 2020-10-27 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
US10385088B2 (en) | 2013-10-02 | 2019-08-20 | Modernatx, Inc. | Polynucleotide molecules and uses thereof |
US10323076B2 (en) | 2013-10-03 | 2019-06-18 | Modernatx, Inc. | Polynucleotides encoding low density lipoprotein receptor |
US11377642B2 (en) | 2013-10-22 | 2022-07-05 | Translate Bio, Inc. | mRNA therapy for phenylketonuria |
EP3501605A1 (en) * | 2013-10-22 | 2019-06-26 | Translate Bio, Inc. | Mrna therapy for argininosuccinate synthetase deficiency |
US11224642B2 (en) | 2013-10-22 | 2022-01-18 | Translate Bio, Inc. | MRNA therapy for argininosuccinate synthetase deficiency |
EP4276176A3 (en) * | 2013-10-22 | 2024-01-10 | Translate Bio, Inc. | Mrna therapy for argininosuccinate synthetase deficiency |
US10208295B2 (en) | 2013-10-22 | 2019-02-19 | Translate Bio, Inc. | MRNA therapy for phenylketonuria |
US9522176B2 (en) | 2013-10-22 | 2016-12-20 | Shire Human Genetic Therapies, Inc. | MRNA therapy for phenylketonuria |
WO2015061500A1 (en) * | 2013-10-22 | 2015-04-30 | Shire Human Genetic Therapies, Inc. | Mrna therapy for argininosuccinate synthetase deficiency |
US10709779B2 (en) | 2014-04-23 | 2020-07-14 | Modernatx, Inc. | Nucleic acid vaccines |
US10022435B2 (en) | 2014-04-23 | 2018-07-17 | Modernatx, Inc. | Nucleic acid vaccines |
US9872900B2 (en) | 2014-04-23 | 2018-01-23 | Modernatx, Inc. | Nucleic acid vaccines |
EP3981437A1 (en) * | 2014-04-23 | 2022-04-13 | ModernaTX, Inc. | Nucleic acid vaccines |
EP3134131A4 (en) * | 2014-04-23 | 2018-06-13 | ModernaTX, Inc. | Nucleic acid vaccines |
EP3134131B1 (en) | 2014-04-23 | 2021-12-22 | ModernaTX, Inc. | Nucleic acid vaccines |
AU2015249553B2 (en) * | 2014-04-23 | 2021-03-04 | Modernatx, Inc. | Nucleic acid vaccines |
EP4023249A1 (en) * | 2014-04-23 | 2022-07-06 | ModernaTX, Inc. | Nucleic acid vaccines |
US11884692B2 (en) | 2014-04-25 | 2024-01-30 | Translate Bio, Inc. | Methods for purification of messenger RNA |
US10155785B2 (en) | 2014-04-25 | 2018-12-18 | Translate Bio, Inc. | Methods for purification of messenger RNA |
US9850269B2 (en) | 2014-04-25 | 2017-12-26 | Translate Bio, Inc. | Methods for purification of messenger RNA |
US11059841B2 (en) | 2014-04-25 | 2021-07-13 | Translate Bio, Inc. | Methods for purification of messenger RNA |
US10286086B2 (en) | 2014-06-19 | 2019-05-14 | Modernatx, Inc. | Alternative nucleic acid molecules and uses thereof |
US10407683B2 (en) | 2014-07-16 | 2019-09-10 | Modernatx, Inc. | Circular polynucleotides |
US10072057B2 (en) | 2014-11-10 | 2018-09-11 | Modernatx, Inc. | Alternative nucleic acid molecules containing reduced uracil content and uses thereof |
EP3041948A1 (en) | 2014-11-10 | 2016-07-13 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules containing reduced uracil content and uses thereof |
US9751925B2 (en) | 2014-11-10 | 2017-09-05 | Modernatx, Inc. | Alternative nucleic acid molecules containing reduced uracil content and uses thereof |
US10864267B2 (en) | 2014-12-05 | 2020-12-15 | Translate Bio, Inc. | Messenger RNA therapy for treatment of articular disease |
WO2016090262A1 (en) | 2014-12-05 | 2016-06-09 | Shire Human Genetic Therapies, Inc. | Messenger rna therapy for treatment of articular disease |
US9943595B2 (en) | 2014-12-05 | 2018-04-17 | Translate Bio, Inc. | Messenger RNA therapy for treatment of articular disease |
US11491112B2 (en) | 2015-04-17 | 2022-11-08 | CureVac Manufacturing GmbH | Lyophilization of RNA |
US11446250B2 (en) | 2015-04-17 | 2022-09-20 | Curevac Real Estate Gmbh | Lyophilization of RNA |
US11534405B2 (en) | 2015-05-20 | 2022-12-27 | Curevac Ag | Dry powder composition comprising long-chain RNA |
US11433027B2 (en) | 2015-05-20 | 2022-09-06 | Curevac Ag | Dry powder composition comprising long-chain RNA |
DE112016002962T5 (en) | 2015-06-30 | 2018-05-24 | Ethris Gmbh | Family of ATP-binding cassette-encoding polyribonucleotides and formulations thereof |
WO2017001570A2 (en) | 2015-06-30 | 2017-01-05 | Ethris Gmbh | Atp-binding cassette family coding polyribonucleotides and formulations thereof |
EP3913054A2 (en) | 2015-06-30 | 2021-11-24 | Ethris GmbH | Atp-binding cassette family coding polyribonucleotides and formulations thereof |
US10702597B2 (en) | 2015-07-21 | 2020-07-07 | Modernatx, Inc. | CHIKV RNA vaccines |
US11007260B2 (en) | 2015-07-21 | 2021-05-18 | Modernatx, Inc. | Infectious disease vaccines |
US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
US10449244B2 (en) | 2015-07-21 | 2019-10-22 | Modernatx, Inc. | Zika RNA vaccines |
US10392341B2 (en) | 2015-09-17 | 2019-08-27 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
US10266485B2 (en) | 2015-09-17 | 2019-04-23 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
US11220476B2 (en) | 2015-09-17 | 2022-01-11 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
US10442756B2 (en) | 2015-09-17 | 2019-10-15 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
US11434486B2 (en) | 2015-09-17 | 2022-09-06 | Modernatx, Inc. | Polynucleotides containing a morpholino linker |
US11872278B2 (en) | 2015-10-22 | 2024-01-16 | Modernatx, Inc. | Combination HMPV/RSV RNA vaccines |
EP3364983A4 (en) * | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | Respiratory virus vaccines |
EP3718565A1 (en) * | 2015-10-22 | 2020-10-07 | ModernaTX, Inc. | Respiratory virus vaccines |
US11235052B2 (en) | 2015-10-22 | 2022-02-01 | Modernatx, Inc. | Chikungunya virus RNA vaccines |
EP3365007A4 (en) * | 2015-10-22 | 2019-07-03 | ModernaTX, Inc. | Broad spectrum influenza virus vaccine |
EP3364980A4 (en) * | 2015-10-22 | 2019-07-10 | ModernaTX, Inc. | Nucleic acid vaccines for varicella zoster virus (vzv) |
US10543269B2 (en) | 2015-10-22 | 2020-01-28 | Modernatx, Inc. | hMPV RNA vaccines |
US11484590B2 (en) | 2015-10-22 | 2022-11-01 | Modernatx, Inc. | Human cytomegalovirus RNA vaccines |
US10517940B2 (en) | 2015-10-22 | 2019-12-31 | Modernatx, Inc. | Zika virus RNA vaccines |
US10238731B2 (en) | 2015-10-22 | 2019-03-26 | Modernatx, Inc. | Chikagunya virus RNA vaccines |
US10124055B2 (en) | 2015-10-22 | 2018-11-13 | Modernatx, Inc. | Zika virus RNA vaccines |
EP3364982A4 (en) * | 2015-10-22 | 2019-04-17 | ModernaTX, Inc. | Sexually transmitted disease vaccines |
US10064934B2 (en) | 2015-10-22 | 2018-09-04 | Modernatx, Inc. | Combination PIV3/hMPV RNA vaccines |
US10933127B2 (en) | 2015-10-22 | 2021-03-02 | Modernatx, Inc. | Betacoronavirus mRNA vaccine |
EP3364981A4 (en) * | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | Human cytomegalovirus vaccine |
US11278611B2 (en) | 2015-10-22 | 2022-03-22 | Modernatx, Inc. | Zika virus RNA vaccines |
EP3364950A4 (en) * | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | Tropical disease vaccines |
US11643441B1 (en) | 2015-10-22 | 2023-05-09 | Modernatx, Inc. | Nucleic acid vaccines for varicella zoster virus (VZV) |
US10064935B2 (en) | 2015-10-22 | 2018-09-04 | Modernatx, Inc. | Human cytomegalovirus RNA vaccines |
EP3365009A4 (en) * | 2015-10-22 | 2019-07-03 | ModernaTX, Inc. | Herpes simplex virus vaccine |
US10716846B2 (en) | 2015-10-22 | 2020-07-21 | Modernatx, Inc. | Human cytomegalovirus RNA vaccines |
EP3365008A4 (en) * | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | Respiratory syncytial virus vaccine |
US10675342B2 (en) | 2015-10-22 | 2020-06-09 | Modernatx, Inc. | Chikungunya virus RNA vaccines |
US10702600B1 (en) | 2015-10-22 | 2020-07-07 | Modernatx, Inc. | Betacoronavirus mRNA vaccine |
US10702599B2 (en) | 2015-10-22 | 2020-07-07 | Modernatx, Inc. | HPIV3 RNA vaccines |
EP4011451A1 (en) * | 2015-10-22 | 2022-06-15 | ModernaTX, Inc. | Metapneumovirus mrna vaccines |
US10383937B2 (en) | 2015-10-22 | 2019-08-20 | Modernatx, Inc. | Human cytomegalovirus RNA vaccines |
US10272150B2 (en) | 2015-10-22 | 2019-04-30 | Modernatx, Inc. | Combination PIV3/hMPV RNA vaccines |
WO2017100562A1 (en) | 2015-12-09 | 2017-06-15 | Alexion Pharmaceuticals, Inc, | Modified mrna encoding a uridine diphopsphate glucuronosyl transferase and uses thereof |
US10485885B2 (en) | 2015-12-10 | 2019-11-26 | Modernatx, Inc. | Compositions and methods for delivery of agents |
US11285222B2 (en) | 2015-12-10 | 2022-03-29 | Modernatx, Inc. | Compositions and methods for delivery of agents |
US10556018B2 (en) | 2015-12-10 | 2020-02-11 | Modernatx, Inc. | Compositions and methods for delivery of agents |
US10207010B2 (en) | 2015-12-10 | 2019-02-19 | Modernatx, Inc. | Compositions and methods for delivery of agents |
US10799463B2 (en) | 2015-12-22 | 2020-10-13 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
US10195156B2 (en) | 2015-12-22 | 2019-02-05 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
WO2017127750A1 (en) | 2016-01-22 | 2017-07-27 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
WO2017180917A2 (en) | 2016-04-13 | 2017-10-19 | Modernatx, Inc. | Lipid compositions and their uses for intratumoral polynucleotide delivery |
US10730924B2 (en) | 2016-05-18 | 2020-08-04 | Modernatx, Inc. | Polynucleotides encoding relaxin |
KR20190026670A (en) * | 2016-05-18 | 2019-03-13 | 모더나티엑스, 인크. | Polynucleotides encoding Relaxin |
KR102533456B1 (en) * | 2016-05-18 | 2023-05-17 | 모더나티엑스, 인크. | Polynucleotides encoding relaxin |
WO2017201350A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding interleukin-12 (il12) and uses thereof |
US11801227B2 (en) | 2016-05-18 | 2023-10-31 | Modernatx, Inc. | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis |
US10835583B2 (en) * | 2016-06-13 | 2020-11-17 | Translate Bio, Inc. | Messenger RNA therapy for the treatment of ornithine transcarbamylase deficiency |
US20180008680A1 (en) * | 2016-06-13 | 2018-01-11 | Rana Therapeutics, Inc. | Messenger RNA Therapy for the Treatment of Ornithine Transcarbamylase Deficiency |
CN109312313A (en) * | 2016-06-13 | 2019-02-05 | 川斯勒佰尔公司 | For treating the mRNA therapy of ornithine transcarbamylase deficiency disease |
US11191849B2 (en) | 2016-06-30 | 2021-12-07 | Arbutus Biopharma Corporation | Compositions and methods for delivering messenger RNA |
US11197927B2 (en) | 2016-10-21 | 2021-12-14 | Modernatx, Inc. | Human cytomegalovirus vaccine |
US11541113B2 (en) | 2016-10-21 | 2023-01-03 | Modernatx, Inc. | Human cytomegalovirus vaccine |
US10695419B2 (en) | 2016-10-21 | 2020-06-30 | Modernatx, Inc. | Human cytomegalovirus vaccine |
US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
EP4035659A1 (en) | 2016-11-29 | 2022-08-03 | PureTech LYT, Inc. | Exosomes for delivery of therapeutic agents |
US11103578B2 (en) | 2016-12-08 | 2021-08-31 | Modernatx, Inc. | Respiratory virus nucleic acid vaccines |
US10273269B2 (en) | 2017-02-16 | 2019-04-30 | Modernatx, Inc. | High potency immunogenic zika virus compositions |
US11253605B2 (en) | 2017-02-27 | 2022-02-22 | Translate Bio, Inc. | Codon-optimized CFTR MRNA |
WO2018157141A1 (en) | 2017-02-27 | 2018-08-30 | Translate Bio, Inc. | Methods for purification of messenger rna |
WO2018157133A1 (en) | 2017-02-27 | 2018-08-30 | Translate Bio, Inc. | Methods for purification of messenger rna |
US11576961B2 (en) | 2017-03-15 | 2023-02-14 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
US11203569B2 (en) | 2017-03-15 | 2021-12-21 | Modernatx, Inc. | Crystal forms of amino lipids |
US10857105B2 (en) | 2017-03-15 | 2020-12-08 | MordernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
US11464848B2 (en) | 2017-03-15 | 2022-10-11 | Modernatx, Inc. | Respiratory syncytial virus vaccine |
US11969506B2 (en) | 2017-03-15 | 2024-04-30 | Modernatx, Inc. | Lipid nanoparticle formulation |
US11497807B2 (en) | 2017-03-17 | 2022-11-15 | Modernatx, Inc. | Zoonotic disease RNA vaccines |
US11173190B2 (en) | 2017-05-16 | 2021-11-16 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of codon-optimized mRNA encoding CFTR |
WO2018231990A2 (en) | 2017-06-14 | 2018-12-20 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase |
US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
WO2018236134A3 (en) * | 2017-06-21 | 2019-03-28 | Korea Research Institute Of Bioscience And Biotechnology | Method and kit for diagnosis of muscle weakness-related diseases using blood biomarker |
WO2019018765A1 (en) | 2017-07-21 | 2019-01-24 | Modernatx, Inc. | Modified mrna encoding a propionyl-coa carboxylase and uses thereof |
WO2019023179A1 (en) | 2017-07-24 | 2019-01-31 | Modernatx, Inc. | Modified mrna encoding a glucose-6-phosphatase and uses thereof |
US11744801B2 (en) | 2017-08-31 | 2023-09-05 | Modernatx, Inc. | Methods of making lipid nanoparticles |
US10653767B2 (en) | 2017-09-14 | 2020-05-19 | Modernatx, Inc. | Zika virus MRNA vaccines |
US11207398B2 (en) | 2017-09-14 | 2021-12-28 | Modernatx, Inc. | Zika virus mRNA vaccines |
US11859215B2 (en) | 2017-11-22 | 2024-01-02 | Modernatx, Inc. | Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders |
US11167043B2 (en) | 2017-12-20 | 2021-11-09 | Translate Bio, Inc. | Composition and methods for treatment of ornithine transcarbamylase deficiency |
WO2019148101A1 (en) | 2018-01-29 | 2019-08-01 | Modernatx, Inc. | Rsv rna vaccines |
US11911453B2 (en) | 2018-01-29 | 2024-02-27 | Modernatx, Inc. | RSV RNA vaccines |
EP3762495A4 (en) * | 2018-03-07 | 2021-12-22 | Icahn School of Medicine at Mount Sinai | Modrna encoding sphingolipid-metabolizing proteins |
US11618893B2 (en) | 2018-06-29 | 2023-04-04 | Icahn School Of Medicine At Mount Sinai | Anc80 encoding sphingolipid-metabolizing proteins for mitigating disease-induced tissue damage |
WO2020023533A1 (en) * | 2018-07-23 | 2020-01-30 | Translate Bio, Inc. | Dry power formulations for messenger rna |
WO2020041793A1 (en) | 2018-08-24 | 2020-02-27 | Translate Bio, Inc. | Methods for purification of messenger rna |
US11174500B2 (en) | 2018-08-24 | 2021-11-16 | Translate Bio, Inc. | Methods for purification of messenger RNA |
WO2020097509A1 (en) | 2018-11-08 | 2020-05-14 | Translate Bio, Inc. | Methods and compositions for messenger rna purification |
US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
EP4223306A3 (en) * | 2019-02-14 | 2023-11-29 | Ethris GmbH | Treatment of ciliopathies |
US11597698B2 (en) | 2019-09-19 | 2023-03-07 | Modernatx, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
US11066355B2 (en) | 2019-09-19 | 2021-07-20 | Modernatx, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
CN114728176A (en) * | 2019-10-09 | 2022-07-08 | 川斯勒佰尔公司 | Compositions, methods and uses of messenger RNA |
WO2021072172A1 (en) * | 2019-10-09 | 2021-04-15 | Translate Bio, Inc. | Compositions, methods and uses of messenger rna |
WO2021154763A1 (en) | 2020-01-28 | 2021-08-05 | Modernatx, Inc. | Coronavirus rna vaccines |
RU2810732C1 (en) * | 2020-02-03 | 2023-12-28 | Хаплнсайенс Инк. | Composition containing hyaluronan/proteoglycan-binding protein 1 for prevention or treatment of lung diseases |
WO2021159040A2 (en) | 2020-02-07 | 2021-08-12 | Modernatx, Inc. | Sars-cov-2 mrna domain vaccines |
WO2021222304A1 (en) | 2020-04-27 | 2021-11-04 | Modernatx, Inc. | Sars-cov-2 rna vaccines |
WO2021159130A2 (en) | 2020-05-15 | 2021-08-12 | Modernatx, Inc. | Coronavirus rna vaccines and methods of use |
CN111929441A (en) * | 2020-08-17 | 2020-11-13 | 南通大学附属医院 | Biomarker and kit used in lung cancer diagnosis and prognosis evaluation |
US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
WO2022067010A1 (en) | 2020-09-25 | 2022-03-31 | Modernatx, Inc. | Multi-proline-substituted coronavirus spike protein vaccines |
CN112553328A (en) * | 2020-12-30 | 2021-03-26 | 浙江大学 | Product for detecting gene expression level and application thereof in preparation of major depressive disorder diagnosis tool |
CN112553328B (en) * | 2020-12-30 | 2022-06-17 | 浙江大学 | Product for detecting gene expression level and application thereof in preparation of major depressive disorder diagnosis tool |
WO2022150717A1 (en) | 2021-01-11 | 2022-07-14 | Modernatx, Inc. | Seasonal rna influenza virus vaccines |
WO2022155524A1 (en) | 2021-01-15 | 2022-07-21 | Modernatx, Inc. | Variant strain-based coronavirus vaccines |
WO2022155530A1 (en) | 2021-01-15 | 2022-07-21 | Modernatx, Inc. | Variant strain-based coronavirus vaccines |
US11622972B2 (en) | 2021-02-19 | 2023-04-11 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
WO2022197624A1 (en) | 2021-03-15 | 2022-09-22 | Modernatx, Inc. | Therapeutic use of sars-cov-2 mrna domain vaccines |
WO2022221335A1 (en) | 2021-04-13 | 2022-10-20 | Modernatx, Inc. | Respiratory virus combination vaccines |
WO2022221440A1 (en) | 2021-04-14 | 2022-10-20 | Modernatx, Inc. | Influenza-coronavirus combination vaccines |
WO2022245888A1 (en) | 2021-05-19 | 2022-11-24 | Modernatx, Inc. | Seasonal flu rna vaccines and methods of use |
WO2023025404A1 (en) | 2021-08-24 | 2023-03-02 | BioNTech SE | In vitro transcription technologies |
WO2023031394A1 (en) | 2021-09-03 | 2023-03-09 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
WO2023069498A1 (en) | 2021-10-22 | 2023-04-27 | Senda Biosciences, Inc. | Mrna vaccine composition |
WO2023073228A1 (en) | 2021-10-29 | 2023-05-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
WO2023092069A1 (en) | 2021-11-18 | 2023-05-25 | Modernatx, Inc. | Sars-cov-2 mrna domain vaccines and methods of use |
WO2023096858A1 (en) | 2021-11-23 | 2023-06-01 | Senda Biosciences, Inc. | A bacteria-derived lipid composition and use thereof |
WO2023107999A2 (en) | 2021-12-08 | 2023-06-15 | Modernatx, Inc. | Herpes simplex virus mrna vaccines |
WO2023122080A1 (en) | 2021-12-20 | 2023-06-29 | Senda Biosciences, Inc. | Compositions comprising mrna and lipid reconstructed plant messenger packs |
WO2023144330A1 (en) | 2022-01-28 | 2023-08-03 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
WO2023196914A1 (en) | 2022-04-08 | 2023-10-12 | Modernatx, Inc. | Influenza nucleic acid compositions and uses thereof |
WO2023230481A1 (en) | 2022-05-24 | 2023-11-30 | Modernatx, Inc. | Orthopoxvirus vaccines |
WO2023227608A1 (en) | 2022-05-25 | 2023-11-30 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
WO2024015890A1 (en) | 2022-07-13 | 2024-01-18 | Modernatx, Inc. | Norovirus mrna vaccines |
WO2024050483A1 (en) | 2022-08-31 | 2024-03-07 | Modernatx, Inc. | Variant strain-based coronavirus vaccines and uses thereof |
WO2024084089A1 (en) | 2022-10-21 | 2024-04-25 | BioNTech SE | Methods and uses associated with liquid compositions |
WO2024083345A1 (en) | 2022-10-21 | 2024-04-25 | BioNTech SE | Methods and uses associated with liquid compositions |
DE202023106198U1 (en) | 2022-10-28 | 2024-03-21 | CureVac SE | Nucleic acid-based vaccine |
WO2024102434A1 (en) | 2022-11-10 | 2024-05-16 | Senda Biosciences, Inc. | Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs |
Also Published As
Publication number | Publication date |
---|---|
HK1208352A1 (en) | 2016-03-04 |
AU2013271392A1 (en) | 2015-01-15 |
JP2017206567A (en) | 2017-11-24 |
US20150157565A1 (en) | 2015-06-11 |
AU2018203310B2 (en) | 2020-05-14 |
CN104519915A (en) | 2015-04-15 |
US20220226236A1 (en) | 2022-07-21 |
CA2876155A1 (en) | 2013-12-12 |
US20190216730A1 (en) | 2019-07-18 |
ES2864878T3 (en) | 2021-10-14 |
EP2858679A1 (en) | 2015-04-15 |
AU2013271392B2 (en) | 2018-02-15 |
EP2858679A4 (en) | 2016-01-13 |
US11090264B2 (en) | 2021-08-17 |
EA201492055A1 (en) | 2015-11-30 |
JP2019065052A (en) | 2019-04-25 |
AU2018203310A1 (en) | 2018-05-31 |
JP6561378B2 (en) | 2019-08-21 |
HK1208618A1 (en) | 2016-03-11 |
JP6913699B2 (en) | 2021-08-04 |
BR112014030677A2 (en) | 2022-07-19 |
EP2858679B1 (en) | 2021-02-24 |
JP2015520195A (en) | 2015-07-16 |
US10245229B2 (en) | 2019-04-02 |
CA2876155C (en) | 2022-12-13 |
MX2014015041A (en) | 2015-06-17 |
EP3884949A1 (en) | 2021-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220226236A1 (en) | Pulmonary Delivery of MRNA to Non-lung Target Cells | |
US10940207B2 (en) | Ice-based lipid nanoparticle formulation for delivery of mRNA | |
US20220249699A1 (en) | COMPOSITIONS AND METHODS FOR mRNA DELIVERY | |
US20220257724A1 (en) | Di-thioester cationic lipids | |
US20220177423A1 (en) | Cystine cationic lipids | |
CA3100254A1 (en) | Thioester cationic lipids | |
EP3959195B1 (en) | Thioester cationic lipids | |
EP3883917B1 (en) | Cationic lipid compounds and compositions thereof for use in the delivery of messenger rna | |
US20210261502A1 (en) | PolyAnionic Delivery of Nucleic Acids | |
US20230071228A1 (en) | 2,5-dioxopiperazine lipids with intercalated ester, thioester, disulfide and anhydride moieities | |
US20230226219A1 (en) | Peg lipidoid compounds | |
US20220071905A1 (en) | Peg lipidoid compounds | |
US20220226244A1 (en) | Macrocyclic lipids | |
US20220016029A1 (en) | Multi-peg lipid compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13800103 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2876155 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2015516249 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2014/015041 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201492055 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013800103 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2013271392 Country of ref document: AU Date of ref document: 20130607 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014030677 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112014030677 Country of ref document: BR Kind code of ref document: A2 Effective date: 20141208 |
|
ENPC | Correction to former announcement of entry into national phase, pct application did not enter into the national phase |
Ref document number: 112014030677 Country of ref document: BR Kind code of ref document: A2 Free format text: ANULADA A PUBLICACAO CODIGO 1.3 NA RPI NO 2425 DE 27/06/2017 POR TER SIDO INDEVIDA. |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112014030677 Country of ref document: BR Kind code of ref document: A2 Free format text: APRESENTE O COMPLEMENTO DO TEXTO EM PORTUGUES, ADAPTADO A NORMA VIGENTE, DO PEDIDO CONFORME DEPOSITO INTERNACIONAL INICIAL (RELATORIO DESCRITIVO E DESENHO, SE HOUVER), CONFORME DETERMINA A RESOLUCAO INPI PR NO 77/2013 DE 18/03/2013, ART. 5O E 7O. |
|
ENP | Entry into the national phase |
Ref document number: 112014030677 Country of ref document: BR Kind code of ref document: A2 Effective date: 20141208 |